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ABSTRACT 
Neuronal nicotinic acetylcholine receptors (nAChRs) are implicated in several 
diseases of the central nervous system, including Alzheimer’s and Parkinson’s 
diseases. They play a role in modulating release of neurotransmittors and in the 
development and intervention of brain seizures and neurodegeneration caused by 
organophosphate poisoning, a major lethal threat in developing countries.  
 
A method was developed to screen drugs for effects on nAChR. The method uses the 
ratiometric Ca2+-probe fura-2 to measure, with the aid of a plate reader, nicotine 
induced responses in the human neuroblastoma cell line SH-SY5Y. The method was 
validated using published data for the Alzheimer drug memantine.  
 
Drugs that show effects against tremor and brain seizures were characterised, 
including the Parkinson drugs biperiden, procyclidine, and trihexphenidyl. These 
drugs all blocked nAChR with an IC50 in a narrow range from 0.75 µM to 1.5 µM. 
The potencies of the drugs at the nAChR were greater than at the NMDA receptors, 
implicating a relevance of drug effects on nAChR in the mechanisms of inhibition of 
seizures. The nAChR block of the drugs were use- and voltage-dependent, features 
particularly suitable for a drug used to restrain epileptogenic seizures. Caramiphen, a 
potent antagonist at muscarinic acetylcholine receptors, also blocks nAChR with an 
IC50 of 0.3 µM.  
 
The novel NMDA-receptor blocker gacyclidine (GK11) was shown to block the 
nAChR with an IC50 of 0.3 µM for its racemate and 0.16 µM for the pure (-)-isomer. 
The novel finding that gacyclidine blocks nAChR makes this receptor a good 
candidate for the “non-NMDA” binding sites that have been established, but not yet 
identified, for gacycyclidine.  
 
Several novel bis-quarternary pyridine compounds inhibited nAChR with IC50 values 
inversely correlated with the length of the carbon chain linker, differing from the 
relative potencies of the drugs at muscle nAChR. This finding is, because of 
ganglionic blockade, highly relevant in selecting a suitable candidate to combat 
organophosphate poisoning. 
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ABBREVIATIONS 
ACh    Acetylcholine  
AChE    Acetylcholine esterase 
AD    Alzheimer’s disease 
AMP    Adenosine monophosphate 
ATP    Adenosine trisphosphate 
 [Ca2+]i    Intracellular calcium concentration 
CAM    Calmodulin 
cAMP    cyclic AMP 
CCD    Charge coupled device 
CICR    Calcium induced calcium release 
CNS    Central nervous system 
DMSO    Dimethyl sulfoxide 
DSTL     Defence Science and Technology Laboratories 
EC50 Concentration giving 50% of the maximal cellular 
response 
ED50    Effective dose in 50% of the tested animals 
EDTA    Ethylenediaminetetraacetic acid 
ER    Endoplasmatic reticulum 
FBS    Foetal Bovine Serum 
G    Gravitational Force 
HS    Horse Serum 
IC50    Concentration inhibiting 50% of the maximal cellular 
    response 
IP3    Inositol 1,4,5 triphosphate 
Kd    Effective dissociation constant  
mAChR   Muscarinic acetylcholine receptor 
nAChR   Nicotinic acetylcholine receptor 
NMDA   N-methyl-D-aspartate  
NMDA-R   NMDA receptor 
OP    Organophosphate 
PBS    Phosphate Buffered Saline 
PD    Parkinson’s disease 
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PMCA    Plasma-membrane Ca2+-ATPase  
ROS    Reactive oxygen species 
SE    Standard Error 
SEM    Standard Error of the Mean 
SERCA   Sarco/endoplasmatic Ca2+ ATPase 
UV    Ultra violet 
VOCC    Voltage Operated Ca2+-channels 
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1  INTRODUCTION 
1.1 Background 
Acetylcholine (ACh) is a major neurotransmitter both in the central and the peripheral 
nervous system. There are two distinct classes of ACh receptors; ligand gated ion 
channels and metabotropic receptors, called nicotinic and muscarinic acetylcholine 
receptors respectively (nAChR and mAChR), due their sensitivity to the plant 
alkaloids nicotine and muscarine (Taylor and Brown 2006). 
 
Neuronal nAChRs are found throughout the central nervous system (CNS). They are 
thought to have mainly modulatory functions on neurons. Presynaptically they 
modulate the release of different neurotransmittors. They are also present post-
synaptically, but to a lesser degree. (Gotti et al. 2006a).  
 
Many drugs used in the treatment of CNS disorders target glutamatergic receptors and 
mAChRs. Some also have effects on nAChR, although these are not well 
characterised. Amongst these are anti-cholinergic Parkinson drugs and possible 
countermeasure agents to organophosphate (OP) poisoning. 
 
OP poisoning is a major cause of death in the developing world, where 
organophosphates are used as pesticides (Buckley et al. 2004). Organophosphates 
have also been used as chemical warfare agents, although prohibited by the Geneva 
gas protocol, and in terrorist attacks (Solberg and Belkin 1997).  
 
OP irreversibly inhibit the enzyme acetylcholine esterase (AChE), and causes 
extracellular accumulation of ACh. This, in turn, leads to excess stimulation of 
mAChR and nAChR (Taylor 1995). The mechanisms for seizures induced by OP 
poisoning include both cholinergic and glutamatergic effects (Solberg and Belkin 
1997). None of the current treatment of OP poisoning include known blockers of the 
nAChRs (Sheridan et al. 2005).  
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A number of clinically used anti-cholinergic Parkinson drugs have been shown to be 
effective against OP-induced brain seizures (Shih et al. 1999). Notably, procylidine, 
biperiden and trihexphenidyl are mAChR antagonists and are also antagonists at 
NMDA-receptors (NMDA-R). The effects of these drugs at nAChR have not yet been 
determined.  
 
Gacyclindine is a novel NMDA-R blocker with high affinity and apparently less 
neurotoxicity than other NMDA-R blockers (Hirbec et al. 2001a). Gacylidine is a 
phencyclidine (PCP)-derivate and is neuroprotective in animal models of 
excitotoxicity. The presence of at least one additional binding site distinct from 
NMDA-R has been established in rat brain and was implicated in the mechanism 
giving reduced neurotoxicity (Hirbec et al. 2001c, 2001b). The authors did not 
succeed in identifying this additional binding site.   
 
HI-6 is an oxime used against OP poisoning. Oxime acts by reactivating action at on 
AChE. In addition, HI-6 was shown to give protective effects against OP poisoning 
when AChE was irreversibly inhibited and this effect was attributed to the block of  
muscle nAChR (Tattersall 1993). To further investigate this protective effect several 
non-oxime analogues of HI-6 have been synthesised, and their inhibitory effects on  
muscle nAChR have been studied (Timperley et al. 2005). The effect of these on the 
CNS and ganglia is not known and the compounds have not been tested on neuronal 
nAChR.    
 
No cell line natively expresses the adult muscle nAChR, and therefore muscle tissue 
preparations are widely used as models for muscle nAChR block. No similar model 
tissue exists for receptors in the CNS, although primary cultures of dissected 
hippocampal neurons have been used. Recently, however, a human neuroblastoma 
cell line, SH-SY5Y, was used to study responses for neuronal nAChR (Dajas-
Bailador et al. 2002).  
 
The goal of this thesis was to develop a method for screening the effects of drugs on 
the neuronal nAChR. We then intended to use this method to screen relevant drugs for 
their possible action at nAChR, and if any were found, to characterise and quantify 
the inhibition. 
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1.2 Cellular calcium metabolism and signalling 
The divalent cation Ca2+ regulates many activities in different cells, e.g. muscle 
contraction, carbohydrate metabolism, secretion, fertilization, neuronal excitability, 
cell growth, secretion, mitogenesis, and apotosis (Berridge and Bootman 1996; 
Alberts et al. 2002; Bird and Putney 2006). The changes in Ca2+ concentrations in the 
cytosol are subject to strict regulation, and are described in further detail below.  
1.2.1 Plasma membrane Ca2+-channels 
There are three main types of Ca2+ channels in the plasma membrane;  
voltage operated Ca2+ channels, ligand-gated ion-channels, and store operated Ca2+-
channels. 
 
Many different ligand-gated ion channels exist in the CNS and they are activated by 
the binding of agonists like glutamate, ACh or ATP. Most are mainly permeable to 
Na+, and exert their effect by the depolarisation of the cell membrane (Alberts et al. 
2002). A few ligand-gated ion channels have a significant permeability to Ca2+ as 
well; among the most notable in the CNS are the NMDA-receptor (NMDA-R) (Hassel 
and Dingledine 2006) and the nicotinic α7 homomeric receptor (Jensen et al. 2005; 
Hassel and Dingledine 2006). Neither receptor is selectively permeable to Ca2+, but 
both show significant permeability to Na+ as well, and may therefore give both a 
Ca2+-rise in the cells and a depolarisation of the cell membrane.  
 
Voltage operated Ca2+-channels (VOCC) open in response to depolarisation of the 
plasma membrane and allow extracellular Ca2+ to enter the cell (Berridge and 
Bootman 1996). They are found in a variety of excitable cells including neurons, 
myocytes and endocrine cells (Bird and Putney 2006). There are at least five different 
types of VOCC, differing in their gating kinetics, conductance and mode of 
inactivation. A main distinguishing feature is the depolarisation required to activate 
the channels. In particular L-type VOCC require a large depolarisation to open and 
are frequently activated as a consequence of depolarisation, giving rise to a large and 
sustained Ca2+-influx  (Dunlap et al. 1995; Berridge and Bootman 1996).  
 
Store-operated Ca2+-channels regulate what is known as capacitive calcium entrance. 
They respond do the depletion of intracellular stores, mainly in the endoplasmatic 
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reticulum (ER). They are mainly found in non-excitable cells, but also in some 
excitable cells (Parekh and Putney 2005; Bird and Putney 2006). 
 
1.2.2 Ca2+ release from intracellular Ca2+-stores 
The main intracellular Ca2+-stores in neuronal cells are the endoplasmatic reticulum 
(ER) and the mitochondria.  
 
Ca2+ accumulates in the ER through the sarco/endoplasmatic reticulum  
Ca2+ ATPase (SERCA). SERCA uses the chemical energy of ATP to transport Ca2+ 
against its large electrochemical gradient from the cytosol to the ER. The ER releases 
Ca2+ to the cytosol and is involved in the Ca2+-signalling through two distinct types of 
receptor; the IP3-receptor and the ryanodine receptor.  
 
Inositol 1,4,5 trisphosphate (IP3) is a second messenger that releases Ca2+ from the ER 
via intracellular receptors. It is produced in the plasma membrane by cleavage of 
inositol containing phospholipids by PI phospholipase C. The cleavage is usually 
induced by the activation of certain G-protein coupled receptors, among them some 
muscarinic acetylcholine receptors (M1, M3, M5) (Heacock and Fisher 2006). Binding 
of IP3 to its receptor opens a Ca2+-channel and results in increased cytosolic Ca2+. 
Activation of IP3 receptor channels is the main pathway to increased Ca2+ in  
non-excitable cells. It is also important in many neuronal cells, in response to 
neurotransmitters that work through G-protein coupled receptors (in particular those 
that work through the Gαq-subunit) (Berridge and Bootman 1996; Bird and Putney 
2006). Ca2+ is a positive allosteric modulator of the IP3 receptor, giving calcium 
induced calcium release (CICR) from the ER, although IP3 is required for channel 
opening (Berridge 1998).  
 
CICR is normally associated with the ryanodine receptor. The ryanodine receptor is 
so named because of its strong affinity to the plant alkaloid ryanodine. The receptor 
opens in response to increased cytosolic Ca2+, either from extracellular sources or 
from activation of IP3-receptors. This process represent an internal amplification of 
the Ca2+-signal, and its importance may vary in different cells (Berridge 1998; Bird 
and Putney 2006). In the neuroblastoma cell line SH-SY5Y, for example, 
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approximately 40% of the Ca2+ released by nicotine is released by secondary 
activation of the ryanodine receptors (Dajas-Bailador et al. 2002).   
1.2.3 Mechanisms of Ca2+-responses in the cell 
Ca2+ may bind to - and regulate the activity of - several proteins in the cell. The best 
described of these proteins is calmodulin (CAM), which is found in all eukaryotic 
cells. The binding of Ca2+ to CAM induces a conformational change in CAM which 
imparts signalling information to a number of different molecules. Ca2+-CAM 
activates a number of kinases, including general CAM kinases and more specialised 
kinases like myosin light chain kinase and elongation factor kinase. Calcineurin is a 
CAM-dependent protein phosphatase that plays an important role in the activation of 
lymphocytes and is the target of the clinically used immunosuppressant drugs 
ciclosporin and tacrolimus. CAM also regulates the secretion of Ca2+ by activation of 
the plasmalemmal membrane Ca2+ ATPase (PMCA). CAM also regulates formation 
of other second messengers including cyclic AMP (cAMP), nitric oxide (NO) and IP3. 
A variety of cytoskeletal proteins, including tau and neuromodulin, are also regulated 
by CAM (reviewed in Berridge and Bootman 1996; Rang et al. 2003; Bird and Putney 
2006).  
 
Some effects are not mediated by CAM, but instead by direct effects of Ca2+ on target 
proteins. Most notable are the effects on Ca2+ on the secretion of neurotransmitters 
and contraction of skeletal muscle. In neurons, vesicles with neurotransmitter are 
docked at plasma membrane, but do not secrete their contents until a local rise in Ca2+ 
activates certain proteins and induces fusion of the vesicle to the plasma membrane 
and exocytosis (Alberts et al. 2002). In skeletal muscle the binding of Ca2+ to the 
protein troponin leads to disinhibition of myosin ATPase and the contraction of the 
muscle (Bird and Putney 2006).  
 
Ca2+ is the key factor in the process of neurodegeneration known as excitotoxicity. 
Excitotoxicity is the mechanism where excessive stimulation of the neuron by 
glutamate causes cell death. It is an important mechanism for cell death implicated in 
a variety of different diseases and conditions, including Parkinson’s disease, 
Alzheimer’s disease, ischemic brain damage, motor neuron diseases, and  
OP poisoning (Solberg and Belkin 1997; Rang et al. 2003; Shaw 2005). The main 
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neurotransmitter behind this toxicity is glutamate. Excessive activation of different 
glutamate receptors results in increased cytosolic Ca2+, which may result in increased 
production of reactive oxygen species (ROS) and NO, mitochondrial dysfunction, 
plasma membrane damage, and eventually apoptosis and necrosis (Rang et al. 2003). 
1.2.4 Control of the cytosolic Ca2+-concentration  
For Ca2+ to work as an intracellular messenger, cells must maintain a low level of 
Ca2+ compared to the surroundings. Compared to the extra cellular levels of Ca2+ 
(~10-3 M), the intracellular concentration of  Ca2+ is very low, 10-8-10-7 M (Silver and 
Erecinska 1990). 
 
Several mechanisms exist to restore the cytosolic Ca2+-level after signalling. The most 
important are the Na+/Ca2+-exchanger, the plasmalemmal membrane Ca2+-ATPase 
(PMCA), the sarco/endoplasmatic reticulum Ca2+ ATPase (SERCA), and the 
mitochondrial uptake. The Na+/Ca2+-exchanger is found in the plasma membrane and 
uses the electrochemical gradient for Na+ to extrude Ca2+ from the cell. The PMCA 
uses the energy of ATP to transport Ca2+ over the plasma membrane against the large 
electrochemical gradient. SERCA uses the chemical energy of ATP to transport Ca2+ 
against its large electrochemical gradient from the cytosol to the ER.  Unlike the ER, 
mitochondria do not have a specific Ca2+-transporter, but accumulates Ca2+ through 
an electrogenic Ca2+-channel. The energy for driving Ca2+ into the mitochondria 
comes from the large negative membrane potential of the mitochondria. Under resting 
conditions the driving force is not large enough to give a significant increased influx 
of Ca2+ to the mitochondria. Once the threshold is reached, however, the driving force 
for uptake of Ca2+ is substantial. The mitochondrial transporter affinity is low, but the 
capacity is high and it is therefore important under conditions of high intracellular 
load. The transporter capacity of SERCA is much lower, but the affinity is high, 
giving the “final” adjustment to low intracellular levels of Ca2+ (reviewed in Berridge 
and Bootman 1996; Bird and Putney 2006).  
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Figure 1-1 Nicotinic acetylcholine receptor. The five subunits form a pore through the cell membrane 
which allows the passage of Na+ and sometimes Ca2+ into the cell. 
 
Acetylcholine (ACh) exerts its effects on the central nervous system (CNS) through 
two distinct classes of receptors; the muscarinic and nicotinic actylcholine receptors 
(mAChRs and nAChRs, respectively). The mAChRs belong to the superfamily of G-
protein coupled receptors. The mAChRs are coupled either to Ca2+-raise, using 
inositol (1,4,5) trisphosohate (IP3) as a second messenger (subtypes M1, M3, and M5), 
or to inhibition of production of  cAMP (subtypes M2 and M4) (reviewed in Taylor 
and Brown 2006). 
 
Nicotinic acetylcholine receptors (figure 1-1) have three distinct functions. One type 
is found in muscle, where they invoke the end-plate potential and cause the 
contraction. Another type is found in the autonomic ganglia, and are exerting the 
control neurotransmission of the autonomic nerve system (Vander et al. 2001). In the 
CNS several types of receptors exist, their functions are outlined below. The nicotinic 
acetylcholine receptor is a ligand-gated ion channel. This means that a chemical 
signal binds to the receptor and opens the channel to ion flux. It belongs to the family 
of pentameric receptors that also include the GABAA, glycine and 5-HT3-receptors 
(Olsen and Betz 2006). These receptors constitute both the ligand-binding site and 
ionic pore through which the ions can flow when stabilized in the open configuration 
(Bertrand 2005). nAChRs consist of five subunits arranged around the central pore of 
the receptor (Brisson and Unwin 1984). The receptors in the CNS have similar 
composition, and vary mainly in their location relating to the blood brain barrier.  
16 
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Figure 1-2 Top view of neuronal nicotinic receptors. A hetropentameric (left) and a homopentameric 
(right) receptor is shown. The binding sites for acetylcholine is shown in red. The ζ represents a subunit 
the can be of different types, and do not participate in the ligand binding.  
 
For the neuronal nicotinic acetylcholine receptors (figure 1-2) the subunits are 
encoded by nine α (α2-α10) and three β (β2-β4) subunit genes, which are expressed in 
the nervous system and in non-nervous tissue (Gotti et al. 2006a). The α1 and β1 
sununit are expressed in muscle. There are two main groups of neuronal nAChRs; the 
hetropentameric nAChRs usually consist of two α-subunits from the α2-α6-subunits, 
and three β-subunits, while the homopentameric nAChRs are usually formed from α7 
or α9-subunits. The homopentameric nAChRs usually show a faster rate of 
desensitisation and a higher Ca2+-permability than the heteropentameric nAChRs 
(Jensen et al. 2005). 
 
Anatomical and functional evidence suggest that the nAChRs are located at both pre- 
and postsynaptic sites. At presynaptic terminals different subtypes regulate the 
secretion of neurotransmitters in different parts of the brain (Gotti et al. 2006b). 
Subtype localization is specific, and different subtypes may have opposing functions. 
This is consistent with the multitude of functions of nAChRs seen by the diverging 
effects of nicotine on behaviour (Picciotto 2003). 
 
 
 
 
β2 α7
Ch
α7
α7α7
α7α3
β2ξ
α3
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In rats, the heteromeric nAChRs have been implicated in the release of ACh, 
dopamine, noradrenalin and GABA, while the homomeric nAChs (mainly α7) was 
implicated in the release of GABA and glutamate (Jensen et al. 2005). nAChRs also 
appear to play a role in the development of the CNS (Gotti and Clementi 2004). In 
addition to its presynaptic role, nAChRs are also expressed at postsynaptic sites in the 
CNS. The precise role of these receptors has not yet been well defined, they seem to 
mediate fast effects on synaptic transmission and have long-term effects on gene 
expression and metabolic pathways. Presently, the presynaptic nAChRs have received 
the greatest attention and is believed to be of more critical physiological importance 
(Jensen et al. 2005). 
 
Several effects of nAChRs in the brain and ganglia are known. In vitro experiments 
indicate that neuronal nAChRs (in particular α7) may control the development of 
neuronal architecture, stabilise synapse formation, and orient and control neurite 
outgrowth selection by means of various mechanisms, some of which may involve 
Ca2+-influx (Gotti et al. 2006b). nAChRs are neuroprotective in several models of 
neuronal death. The intracellular steps that mediate this neuroprotective effect is not 
yet fully understood, but the effect is Ca2+-dependent and does not involve block of 
glutamate receptor function. Thus, activation of downstream signalling pathways 
appears to be necessary for the prevention of neuronal death, but there is no consensus 
as to which pathway is the most important (Dajas-Bailador and Wonnacott 2004). 
 
nAChRs have been implicated in diseases of the brain. Modifications in the number of 
nAChRs are seen in many different diseases, among these diseases are schizophrenia, 
Tourette’s syndrome, attention deficient hyperactivity disorder, autism, depression 
and anxiety, and the neurodegenerative disorders Alzheimer’s and Parkinson’s 
diseases (AD and PD, respectively). Changes in nAChR expression is also seen in 
aging (Gotti et al. 2006a).  
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The early evidence for the involvement of nAChRs in AD and PD came from 
epidemiological data negatively correlating tobacco smoking with AD and PD. 
Careful studies confirmed the protective effect on tobacco smoking against PD, but 
failed to confirm the protective effect against AD. The pathology responsible for PD 
is the loss of dopaminergic function in the nigro-striatal pathway. There is also a 
dramatic decrease in functioning of the nicotinic cholinergic system that may be 
responsible for the deficit in the dopaminergic pathway and cortical function. Nicotine 
and nicotinic agents have been tested successfully in experimental models of PD, but 
clinical trials with nicotine have given controversial results; some improvement in 
cognitive and motor effects, but also an increase in tremor. In AD there is a decrease 
in the number of brain nAChR, particularly of the heteropentameric receptors. In AD 
nicotine improves perceptual and visual deficits, attention performance and semantic 
memory. Several drugs used against AD have effects on the nAChRs, among them 
memantine and the cholinesterase inhibitors tacrine and galantamine . Clinical trials 
of drugs with effects on nAChRs have so far been disappointing (reviewed in Gotti et 
al. 2006b).  
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1.4 Organophosphate poisoning 
Organophosphates (OP) are a class of highly toxic compounds that includes nerve 
agents, pesticides and insecticides. Although the use of nerve agents is banned by the 
Geneva gas protocol, they were still used by Iraqi forces in the 1980s. Sarin, an OP 
nerve agent, was also used in the 1995 terrorist attack in the Tokyo subway (Solberg 
and Belkin 1997).  
 
The main effect of OP is irreversible inhibition of AChE which results in inhibition of 
the hydrolysis of ACh and the excessive extracellular accumulation of ACh (van 
Helden and Bueters 1999; Sheridan et al. 2005). The main symptoms of OP poisoning 
are all related to the excessive stimulation of the cholingergic receptors: airway 
hypersecretion, bronchoconstriction, bradycardia, gut hypermotility, sweating and 
papillary constriction are all linked to mAChRs, while muscle fasciculation and 
weakness, tachycardia, hypertension, papillary dilatation, and irregular respiration are 
linked to nAChRs, both neuronal, ganglionic and muscular (Sheridan et al. 2005; 
Hassel 2006). CNS symptoms are also observed, among them giddiness, insomnia, 
tension, anxiety, central respiratory depression, ataxia, seizures, and coma (Barthold 
and Schier 2005). The cholinergic input to various brain nuclei gives rise to increased 
glutamatergic and GABAergic activity and causes brain seizures. The seizures 
progress rapidly to status epilepicus, which may lead to profound structural brain 
damage. The seizures and resulting brain damage are initiated by cholinergic  
over-stimulation which triggers seizures in susceptible brain regions. Once the 
seizures have started, non-cholinergic cell systems are progressively recruited and the 
seizures become resistant to muscarinic receptor antagonists. The seizures cause the 
release of excessive amounts of glutamate from affected neurons and the released 
glutamate give rise to excitotoxicity and cell death (Solberg and Belkin 1997).  
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1.4.1 Current treatment of organophosphate poisoning 
The standard treatment for nerve-agent (OP) poisoning currently has two main parts.  
The treatment after exposure usually is atropine sulphate and one of the oximes 
obidoxime, P2S, 2-PAM, HI-6 or TMB4, injected intramuscularly. In some countries, 
including Norway, Great Britain and the United States, a benzodiazepine is added to 
this therapy. Atropine is an antagonist of the mAChRs, and blocks the over-activity of 
the mAChRs caused by organophosphate poisoning. The oximes reactivate AChE and 
reduce the problem of cholinergic over-stimulation. However, after some time, an 
irreversible change occurs in the binding of OP to AChE, and oximes no longer 
effectively reactivate AChE. Benzodiazepines are known anti-seizures drugs, and will 
reduce or stop the seizures observed in OP poisoning. Prophylactic treatment is used 
by the military when the risk of exposure is considered high. Currently, the reversible 
AChE inhibitor pyridostigmin, taken orally, is used by most countries  
(review in Aas 2003).  
1.4.2 The role of nAChRs in organophosphate poisoning 
The current treatment regimens for OP poisoning do not treat the nicotinic effects of 
OP poisoning. OP poisoning gives increased stimulation at all three locations of 
nAChR; the neuromuscular junction, the autonomic ganglia, and the CNS.  At the 
neuromuscular junction OP poisoning results first in muscle fasciculation and then 
weakness or even paralysis (Barthold and Schier 2005). The weakness is probably due 
to desensitisation of the receptor (Sheridan et al. 2005). At the ganglia the excessive 
stimulation causes activation of the autonomic nervous system. While the activation 
of the parasympathetic nervous system is inhibited by the use of atropine, no drug in 
the treatment of the activation of the sympathetic nervous is commonly used, and 
tachycardia and hypertension usually result (Sheridan et al. 2005). The effects of OP 
poisoning on nAChRs have been difficult to assess. Some authors found no effects on 
survival after OP poisoning by the centrally acting nAChR antagonist mecamylamine 
in vivo (Shih et al. 1999), or on seizure activity in an hippocampal model of seizures 
(Harrison et al. 2004). However, a recent study using very high doses of 
mecamylamine did find an improvement in survival in mice. The main symptoms 
alleviated by mecamylamine were irregular respiration and convulsive crawling. It 
was suggested that these effects in the brain stem and that the effect of mecamylamine 
on OP poisoning was related to its effect in these areas of the brain (Hassel 2006). 
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1.5 Adenosin Trisphosphate as a neurotransmitter 
Adenosine triphosphate (ATP) is the major form of energy in all living organisms. 
Somewhat surprisingly it is also an important neurotransmitter in the human body. 
There are two distinct classes of ATP-receptors, P2X-receptors, which are ligand 
gated ion-channels and P2Y-receptors, which are G-protein coupled receptors. Most 
P2Y-receptors in the CNS use IP3 as a second messenger, and thus give an increase in 
intracellular Ca2+. Some P2Y-receptors couple to a decrease in cAMP. Most P2X-
receptors have a fairly large permeability to Ca2+. ATP is usually co-released with 
glutamate, ACh or noradrenalin in the CNS. The main effects of P2X-receptors in the 
brain are in the release of glutamate in the hippocampus (reviewed in Burnstock 2006; 
Linden and Rosin 2006).  
 
1.5.1 Purinergic receptors in astrocytes 
Astrocytes express P2Y1,  P2Y2,  P2Y4 and P2X7 (Nedergaard et al. 2003). All the 
P2Y receptors are linked to the generation of IP3 and subsequent increase in cytosolic 
Ca2+ (Burnstock 2006). As noted above, P2X7 is a ligand gated ion channel. P2X7 
have recently been implicated in induction of apoptosis (Runden-Pran et al. 2005).    
Astrocytes may therefore be used as a simple model of ATP responses in the CNS. 
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1.6 SHSY-5Y – A human neuroblastoma cell line 
The human cell line SK-N-SH was isolated fra a bone marrow metastasis in a four 
year old girl (Biedler et al. 1973). The SK-N-SH cell line contains at least two 
different morphologicaly distinct cell types, one epithelial and one neuroblastoma. 
The cell line SH-SY5Y was cloned from its parent cell line SK-N-SH (Ross et al. 
1983) and is neuroblast-like in appearance, with small to medium length neurites that 
extend radially from the cell body (figure 1-3). SH-SY5Y expresses both muscarinic 
acetylcholine receptors (mainly of the M3 type) (Lambert et al. 1989) and several 
subtypes of nAChRs  (Lukas et al. 1993). SH-SY5Y cells express the subunits α3, α5, 
α7, β2 and β4 (Lukas et al. 1993; Peng et al. 1994). The main functional types of 
nAChRs in SH-SY5Y are thought to be α3β2 and α7. (Dajas-Bailador et al. 2002).  
As SH-SY5Y expresses several of the nAChRs normally found in the CNS, it is a 
useful model of nicotinic receptors in the CNS (Peng et al. 1997; Dajas-Bailador et al. 
2002; Sokolova et al. 2005). 
 
 
Figure 1-3 Phase-contrast photomicrograph of SH-SY5Y cells, passage 20, grown for three days on 
poly-D-lysine treated glass coverslips for single cell imaging. The cells shown are not confluent.  
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1.7 The different drugs investigated 
1.7.1 Anti-cholinergic Parkinson drugs 
 
Figure 1-4 Anti-cholinergic Parkinson drugs: (left to right) biperiden, procyclidine and trihexphenidyl  
 
The anti-cholinergic Parkinson drugs (figure 1-4) are the oldest form of anti-
Parkinson drugs. After the introduction of L-DOPA and other dopamine agonists, 
however, they are not considered as first choice in the treatment of PD. They are now 
mainly used to treat extra-pyramidal side effects of antipsychotic drugs (Aasly 2004). 
They are also used to treat  PD patients that can not use dopamine receptor-agonist  
and are sometimes used as an adjunct to L-DOPA therapy (Standaert and Young 
1995). They have also successfully been used in treatment of dystonia and spasm. 
They are effective against soman-induced seizures in rats both after 5 minutes and 
after 40 minutes. The most potent of these drugs 5 minutes after soman poisoning are 
biperiden (ED50: 0.09 mg/kg) and trihexphenidyl (ED50: 0.17 mg/kg), while 
procyclidine is significantly less potent (ED50: 1.51 mg/kg) (McDonough and Shih 
1993; Shih et al. 1999). This correlates fairly well with the drugs potencies at the 
mACh IC50 of 8.4 nM, 26 nM and 70 nM, respectively (Syvälahti et al. 1988). 
Trihexphenidyl is the most potent 40 minutes after soman poisoning (ED50: 6.49 
mg/kg), followed by procyclidine  (ED50:13,30 mg/kg) with biperiden (ED50: 19,05 
mg/kg) as the least potent. Atropine does not stop seizures 40 minutes after soman 
poisoning (McDonough and Shih 1993; Shih et al. 1999). It has been shown that the 
anti-cholinergic Parkinson drug inhibit the NMDA-R. Their IC50-values for inhibition 
of NMDA-induced responses in cocultures of rat cerebellar granule cells with 
astrocytes are 48µM for biperiden, 3 µM for procyclidine and 50 µM for 
trihexphenidyl (Ring and Tansø, unpublished data). The fact that atropine is not 
effective after 40 minutes is attributed to the recruitment of non-cholinergic pathways, 
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where glutamatergic pathways are thought to be most important (Solberg and Belkin 
1997). The fact that the correlation between the potencies of the drugs at the NMDA-
receptor and their effectiveness at stopping seizures after 40 minute is poor, may 
come down to differences in the pharmacokinetics of the different drugs. Relatively 
few studies on pharmacokinetics have been done on these drugs. The apparent volume 
of distribution (Vd) for trihexphenidyl is unknown, while the Vd for procyclidine and 
biperiden is 1.0 L/kg and 24 L/kg, respectively (Brocks 1999). For biperiden the 
concentration of drug in the brain has been reported as 10 times higher than the 
concentration in blood (Yokogawa et al. 1992). No such data exists for procyclidine 
or trihexphenidyl.  
 
The anti-cholinergic Parkinson drugs have also been tested on effects of nicotine 
induced seizures in vivo. All the anti-cholinergic Parkinson drugs were effective with 
ED50 values of 4.6 mg/kg for biperiden, 3.1 mg/kg for procyclidine and 3.3 mg/kg for 
trihexphenidyl. The mechanism of the inhibition was not determined (Gao et al. 
1998).  
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1.7.2 Memantine 
 
Figure 1-5 Memantine 
 
Memantine (figure 1-5) is used clinically to treat moderate to severe AD at doses of 
up to  20 mg/day (Lundbeck A/S 2006). Clinically memantine shows significant 
positive effects on cognition, mood, behaviour and the ability to perform activities of 
daily living in patients suffering from moderate to severe AD (McShane et al. 2006).  
In humans a dose of 20 mg a day gives a blood serum concentration of 0.5-1 µM 
(Parsons et al. 1999) The unbound amount of drug in the cerebrospinal fluid is  
40%-60% of the drug concentration in serum, giving clinically relevant brain 
concentrations of  about 0.25-0.5 µM memantine (Kornhuber and Quack 1995).  
Memantine is classified as a non-competitive NMDA-R antagonist. Memantine has a 
reported IC50 of 1-3 µM in different systems. The inhibition of the NMDA-R is use-
dependent and strongly voltage-dependent. Despite its relatively low affinity, 
memantine seems to bind selectively to the binding site of (+)-MK-801 (Parsons et al. 
1999).  Several different values have been reported for the IC50-values of memantine 
on nAChR. Memantine blocks the α7-receptors with an IC50 of between 0.3 µM in 
hippocampal neurons (Aracava et al. 2005) and 5 µM in oocyte systems (Maskell et 
al. 2003). It blocks the α4β2-receptors with an IC50 of 7 µM in a stably transfected 
cell line (Buisson and Bertrand 1998). All of these effects were shown to be use-
dependent. In addition to the effects on NMDA-R and nAChR, memantine also blocks 
voltage-operated Ca2+-channels with an IC50 of 62 µM (Parsons et al. 1999). 
Memantine alleviates the convulsions caused by of OP poisoning, but does not stop 
seizures as monitored by EEG (Shih et al. 1999). 
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1.7.3 MK-801 and Gacyclidine  
 
Figure 1-6 (+)-MK-801(left) and (-)-gacyclidine  
 
(+)-MK-801(dizoclopine, figure 1-6) is a pharmacological tool often used to identify 
NMDA-R and NMDA-R dependent processes (Price et al. 1988; Briggs and 
McKenna 1996). It blocks NMDA-R in a voltage dependent manner and has its 
binding site in the ion channel of the receptor (Wong et al. 1986; Foster and Wong 
1987; Price et al. 1988). MK-801 blocks the NMDA-R with an affinity of less than 
100 nM (Wong et al. 1986) It blocks the α4β2 nAChR with an IC50 of 18.7 µM  
(Buisson and Bertrand 1998) and the α7 with an IC50 of 15 µM (Briggs and McKenna 
1996). It is not used clinically because of intolerable side effects (Lipton and 
Rosenberg 1994).   
 
Gacyclidine (GK11) is a novel antagonist of the NMDA-R that binds to the same 
binding site as MK-801. It has been shown to protect against glutamate neurotoxicity 
(Drian et al. 1999). Its (-) isomer has an IC50 of 2.5 nM at the NMDA-R, while its  
(+) - isomer has 10 fold lower potency (Lallement et al. 1997). The (-) isomer is more 
potent than the (+) in protection of glutamate induced toxicity, but no significant 
difference was found between the (-) isomer and the racemate (Drian et al. 1999). 
Gacyclidine is currently in clinical trials for treatment of acute traumatic brain injury 
(Lepeintre et al. 2004). It has been tested for acute spinal cord injury, but the results 
were disappointing (Fehlings and Baptiste 2005). It has also been shown to be 
neuroprotective against soman poisoning in vivo (Lallement et al. 1997; Bhagat et al. 
2005). No data are currently available on the effect of gacyclidine on the nAChRs. 
Gacyclidine have, however, been shown to bind to a site distinct from the NMDA site 
in the brain of rats (Hirbec et al. 2001b). 
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1.7.4 Caramiphen 
 
Figure 1-7 Caramiphen 
 
Caramiphen (figure 1-7) is used clinically as an antitussive agent (Reisine and 
Pasternak 1995). It is an antagonist at both the mAChR and the NMDA-R. On the 
mAChR receptor it appears to be selective for the M1 class of receptors with a Ki of 
1,2 nM for M1 and 32 nM at the M2 mAChR (Hudkins et al. 1991). At the NMDA-R 
it has an IC50 in cocultures of rat cerebellar granule cells with astrocytes of 72 µM  
(Ring and Tansø, unpublished data). It is more protective against soman-induced 
seizures than the pure mAChR antagonist scopolamine when given as pre-treatment  
(Raveh et al. 2002). It protects both against soman-induced seizures and brain damage 
when given after exposure to soman, but does not stop seizures 40 minutes after 
soman exposure (Shih et al. 1999; Raveh et al. 2003). No studies of the effect of 
caramiphen on nAChR have been done in vitro, but caramiphen has an ED50 of 7.8 
mg/kg against nicotine induced seizures in vivo (Gao et al. 1998), but the mechanism 
of this block was not clarified.                                                                                                                       
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1.7.5 Novel bis-quarternary pyridine compounds 
N N
n
 
+ +
 
Figure 1-8 General structure of the novel bis-quarternary pyridine compounds tested. n is the chain 
length, varying from 1 to 10 for the compounds tested.  
 
As noted above, the current treatment for OP poisoning does not affect nAChRs. 
However, HI-6, one of the oximes currently used to counter OP poisoning, does show 
an open-channel block of the muscular nicotinic ACh receptors (Tattersall 1993). As a 
result of this, the Defence Science and Technology Laboratories (DSTL) in Porton 
Down, UK, synthesised many analogues of HI-6 (figure 1-8) in order to test them on 
muscular nAChR (Timperley et al. 2005). These compounds are not oximes, but they 
were syntetized to be tested on muscle nAChR. Effects of the drugs on recovery of 
soman poisoned guinea pig diaphragm, a good model of muscle nAChR block, 
appears to be chain-length dependent with a bell-shaped response, where a chain-
length of five gives the best response, while longer or shorter chain-lengths give less 
block. The effects on neuronal nAChR have not been determined.  
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1.8  Objectives 
The objectives of this thesis were:  
   
-  To develop an effective and robust method for screening the effects of drugs at 
neuronal nicotinic acetylcholine receptors (nAChR).  
 
-   To use the method to test effects at neuronal nAChR by memantine, 
caramiphen, biperiden, trihexphenidyl and procyclidine. Of particular interest 
were NMDA-R inhibitors which show promise in the treatment of OP 
poisoning.  
 
-   To use the method to determine the effects at neuronal nAChRs by the novel 
neuroprotective agent gacyclidine, and to compare the effects of its racemate 
with its (-)-isomer. 
 
- To compare the determined in vitro characteristics, with the available in vivo 
data in order to qualitatively asses the relevance of neuronal nAChR effects.  
 
-   To use the method to test for effects of several novel bis-quarternary pyridine 
compounds at neuronal nAChR and to compare these data with the data 
obtained in vitro at muscle nAChR by our collaborators at Porton Down. 
.
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2 MATERIALS AND METHODS 
The main method used in this thesis is based on the measurement of intracellular 
calcium with the aid of fluorescent probes. The cells were loaded with exogenously 
added probes and the intracellular response was monitored by illumination with UV 
or visual light and then recording the fluorescent emission. Classical single cell 
imaging was used as well as a plate reader with cells grown in multi well plates.  
2.1 Chemicals  
Chemical name     Supplier 
Akineton for injection 5 mg/ml   Abbott, Fornebu, Norway 
(biperiden lactate) 
Adenosine triphophate, sodium salt   Sigma-Aldrich, St. Louis, MO 
Atropine sulphate     Sigma-Aldrich, St. Louis, MO 
Calcium chloride (CaCl2)    Merck, Darmstadt, Germany 
Caramiphen edisylate     Sigma-Aldrich, Milwaukee, WI 
Carbachol      Sigma-Aldrich, St. Louis, MO  
Deconex      Borer Chemie, Zuchwil, SUI 
Dimethyl sulphoxide (sterile, water free)  Sigma-Aldrich, St. Louis, MO 
EDTA, 0.02% in PBS     Sigma-Aldrich, St. Louis, MO 
FLIPR Membrane potential assay kit Molecular Devices, 
Sunnyvale,CA 
Fluo-3-AM      Invitrogen, Paisly, UK 
Foetal Bovine Serum     Invitrogen, Paisly, UK 
Fura-2-AM      Invitrogen, Paisly, UK 
(±)-Gacyclidine hydrochloride   Beufort Ipsen, Paris, France 
(-) -Gacyclidine hydrochloride   Beufort Ipsen, Paris, France 
Gentamycin sulphate     Sigma-Aldrich, St. Louis, MO 
Glucose monohydrate     Merck, Darmstadt, Germany 
GlutaMax®      Invitrogen, Paisly, UK 
HI-6 diklorid monohydrat Dr. Boulet, Defence Research 
Establishment Suffield, Ralston, 
Alberta, Canada  
Horse Serum Invitrogen, Paisly, UK 
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Hydrogen chloride (HCl) (Tritisol)   Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2), 30%    Sigma-Aldrich, St. Louis, MO  
Nicotine      Sigma-Aldrich, St. Louis, MO 
Nicotine hydrogentartrate    Sigma-Aldrich, St. Louis, MO 
Nitric acid (HNO3), concentrated   VWR, Fountenay sous Bos, FRA 
Magnesium sulphate heptahydrate (MgSO4·7H2O) Merck, Darmstadt, Germany 
Memantine hydrochloride    Sigma-Aldrich, St. Louis, MO 
Minimum Essential Medium (+Earle’s –Glutamine) VWR, Oslo, Norway 
(+)-MK-801      Sigma-Aldrich, St. Louis, MO  
Penicillin/streptomycin    Invitrogen, Paisly, UK 
Pluronic F-127     Invitrogen, Paisly, UK 
Poly-D-lysine (Molecular weight >300 000 D) Sigma-Aldrich, St. Louis, MO 
Potassium chloride (KCl)    Merck, Darmstadt, Germany 
Probenecid      Sigma-Aldrich, St. Louis, MO 
Procyclidine hydrochloride    Sigma-Aldrich, St. Louis, MO 
Sodium chloride (NaCl)    Merck, Darmstadt, Germany 
Sodium dihyrogenphosphate (NaH2PO4)  Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH)    Merck, Darmstadt, Germany 
Sulphuric acid (H2SO4), concentrated  Merck, Darmstadt, Germany 
Suramine      Sigma-Aldrich, St. Louis, MO 
Trihexphenidyl hydrochloride   Sigma-Aldrich, St. Louis, MO 
Trizma sulphate     Sigma-Aldrich, St. Louis, MO 
(+)-tubocurarine hydrochloride hydrate  Sigma-Aldrich, St. Louis, MO 
Verapamil hydrochloride    Sigma-Aldrich, St. Louis, MO  
 
 
Unless otherwise stated all reagents were of pro analysis quality  
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2.2 Cell culture of SH-SY5Y  
Culture medium for SH-SY5Y 
0.1 mg/ml Gentamycin sulfate      
10 % Foetal Bovine Serum        
Minimum Essential Medium (+ Earle’s + GlutaMax-I®)  
 
SH-SY5Y (The European Collection of Cell Cultures, Salisbury, UK) was kept in 
ampoules at -135 °C in regular medium with the addition of 10% DMSO. The cells 
obtained at generation 14 were scaled up and stored at generation 17. The cells were 
removed from the freezer and left for 1 minute at room temperature before being 
heated to 37 °C in a water bath. The suspension of cells was added to 12 ml of 
medium and this suspension was added to a 75 ml flask (Sarstedt, Nürnbrecht, 
Germany). The cells were then incubated at 36 °C in an atmosphere saturated with 
water vapour and with 5 % CO2 (Forma Scientific CO2 water jacketed incubator, 
Forma Scientific inc., Ohio, USA). The medium was changed after one day to remove 
remnants of DMSO. The medium was changed after 3-4 days.  
 
The cells were split every 6-8 days. The medium was removed and the cells were 
washed once with 2 ml 0.02% EDTA in PBS, this solution was removed, and 1.5 ml 
of EDTA was added. The cells were left for 2 minutes before the cells were detached 
with a light tap on the flask. 10 ml of medium was added to this suspension and 
transferred to a 15 ml tube (Sarstedt, Nürnbrecht, Germany). The suspension was then 
centrifuged for 3 minutes at 100 G (1000 rpm) (IEC centra CL 2, International 
Equipment Company, Tamro LAB, Vantaa, Finland).The supernatant was carefully 
removed, and the cells were resuspended in 5 ml of medium. For further culturing in 
flasks, 500 µl of cell suspension was added to 12 ml of medium, and this suspension 
was transferred to a new flask.  
 
The cells were obtained mycoplasma free, and no further testing on the batches was 
performed as each batch was used for a limited period. There were no problems with 
fungal or bacterial growth in the incubator, which was dedicated to cell lines only. 
Experiments were run on cells from generation 19 to 25. 
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2.3 Measurement of intracellular Ca2+ and membrane potential 
In general, an intracellular fluorescent probe reports changes of a concentration in a 
compartment of the cytoplasm. Visible or ultra violet (UV) light is used to excite the 
cell containing the probe, and fluorescent light that is then emitted by the probe is 
dependent on the concentration of the component it measures. For most probes, the 
binding of the component to be measured to the probe gives changes in the 
fluorescent properties of the probe. The best wavelength to excite the probe is 
determined by recording the excitation spectrum – varying the illumination 
wavelength, and determining which wavelength gives the highest emitted fluorescent 
intensity. 
  
2.3.1 Fura-2, a ratiometric Ca2+-probe 
 
 
Figure 2-1 Fura-2 (pentapotassium salt) 
 
Fura-2 (figure 2-1) is a ratiometric probe. A ratiometric probe does not simply change 
the emitted fluorescent intensity with changing concentrations of Ca2+, but the Ca2+-
bound and Ca2+-free probe has different spectra (figure 2-2). Because of this it is 
possible to excite at two different wavelengths and calculate the ratio of emitted 
fluorescence for the two intensities. (Grynkiewicz et al. 1985). Ratiometric 
measurements are largely independent of cell thickness, uneven probe loading, probe 
leakage and photo bleaching. For example, if probe leaks from the cells during the 
experiment, the intensity will be decreased, but as the calibration depends only on the 
ratio of intensities, the resulting ratio will not be affected (Tsien et al. 1985). To 
determine the ratio, the cells are excited with light alternating between two different 
wavelengths (340 nm and 380 nm), and the emission is measured at a fixed 
wavelength (510 nm).  
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Figure 2-2 The excitation spectra of fura-2 at different wavelengths (from (Invitrogen 2006) 
 
By first calibrating using the ratios obtained with solutions with known concentrations 
of Ca2+ and containing fura-2, it is possible to calculate the intracellular concentration 
of Ca2+ in any given experiment. If the ratio between the intensity at the two 
wavelengths is R, then the free Ca2+ have been shown to be 
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the ratio between the Ca2+-free and the Ca2+-bound form (Grynkiewicz et al. 1985; 
Kao 1994). Several factors may influence the Kd. Values ranging from 145 nM (in 
vitro without Mg2+) to 373 nM (in situ in the astrocyte cell line U373-MG) have been 
reported (Grynkiewicz et al. 1985; Negulescu and Machen 1990; Petr and Wurster 
1997). Fura-2 also shows some temperature dependence in its Kd (Oliver et al. 2000). 
The fluorescence at 380 nm becomes very small when Ca2+ is high, giving a large 
error in the ratio Rmax because of uncertaincies in background corrections. Due to 
these and other uncertainties in calibrating Ca2+-concentrations, responses are 
frequently reported as 340/380-ratio changes only and for the purposes of screening 
the relative potencies and determining IC50 and EC50 values this is adequate (Tsien 
and Harootunian 1990). The workload is significantly reduced by not calibrating in 
each experiments. The error in basal Ca2+-levels has been estimated at 100 nM (Neher 
1989), compared to a basal level of 10 – 100 nM  (Silver and Erecinska 1990). 
Because of these problems the results of experiments with fura-2 will be reported as 
change in ratio, and not as change in intracellular Ca2+-concentration.  
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2.3.2 Fluo-3, a single wavelength Ca2+-probe 
 
 
Figure 2-3 Fluo-3-AM (pentaammonium salt)
 
Fluo-3 (Figure 2-3) is a single wavelength probe. A single wavelength probe does not 
change its excitation or emission spectra as a response to various Ca2+ concentrations, 
but only changes the intensity of the emitted light. The Ca2+-bound form of fluo-3 is 
36-40 times brighter than Ca2+-free probe (Minta et al. 1989). Unlike fura-2, fluo-3 is 
excited by visual light (485 nm), and has fewer problems with autofluorescence from 
cell components and the growth substrate. The results with fluo-3 are reported as 
changes in fluorescence. Typically fluo-3 is the probe of choice for qualitative 
measurements of fast changes in Ca2+-concentration or when a high sensitivity for 
changes in Ca2+ is required. It is ideal for determining whether a drug blocks short 
“spikes” of Ca2+-changes, e.g. from IP3-mediated Ca2+-release. It is used here to 
measure Ca2+-responses of mAChRs as the responses to carbachol in SH-SY5Y is 
mainly due to IP3-mediated Ca2+-realease (Lambert et al. 1989; Taylor and Brown 
2006). 
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2.3.3 The use of AM esters to load cells 
 
Figure 2-4 Fluo-3-AM and fura-2-AM 
 
Both fluo-3 and fura-2 (figure 2-4) were used as their acetomethoxy (AM) esters. The 
AM group is used to mask the negative charges of these tetrecarboxylate probes. The 
uncharged and hydrophobic esters readily pass the lipid cell membrane and gain 
access to the interior of the cell. The carboxyl groups of the probes are important in 
sensing the Ca2+; therefore, the AM group must be removed once the ester has entered 
the cell. The AM group is labile to enzymatic hydrolysis by intracellular esterases. 
This hydrolysis yields the tetracarboxylate form, which is effectively trapped inside 
the cells, resulting in an accumulation of the tetracarboxylate probe inside the cell  
(Tsien 1981; Kao 1994).  
2.3.4 The membrane potential probe, FMP 
The FLIPR Membrane Potential probe (FMP) is a novel fluorescent probe that 
responds to changes in membrane potential. Unlike the Ca2+-probes, the FMP is not 
distributed to cytosol, but rather remains at the cell membrane. The FMP is much 
faster than traditional membrane potential probe DiBAC4(3), and its response-time is 
comparable to patch-clamp responses (Baxter et al. 2002). It is also the most sensitive 
fluorescent membrane potential probe currently available (Wolff et al. 2003). The 
probe was prepared in accordance with the recommended procedure; 1 vial was 
dissolved in 10 ml buffer. This solution was the frozen at -135 °C for later use.  
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2.4 Preparation of cell cultures in multiwell plates 
A suitable method for screening should ideally have a number of characteristics: It 
should be quick, simple to use and robust against small variations in the experimental 
procedure. To be able to screen several drugs quickly a plate reader was used (BMG 
Fluostar Optima, BMG labtech, Offenburg, Germany). SH-SY5Y was chosen as the 
model system for central nicotinic effects. A method using fluo-3 has previously been 
described (Dajas-Bailador et al. 2002), but as the amount of fluo-3 used was rather 
high (10 µM) and fluo-3 is a single wavelength probe, it was decided to try to develop 
a more sensitive method using fura-2. As fura-2 is excited in the ultraviolet range, 
there is a considerable problem with autofluorescence, particularly from polystyrene 
based substrates. The requirements for a good growing substrate for this method is 
that it must have an acceptable (low) amount of autofluorescence at the wavelengths 
used and support the growth of the SH-SY5Y at sufficiently high density and thus 
give a good signal to noise ratio.  
 
A number of different approaches were attempted as outlined below. The protocol 
that was accepted utilized a new, commercially available multiwell plate, Corning 
CellBind.  
 
2.4.1 Treatment of polystyrene with ozone 
Clear polystyrene sheets were cut to fit the measuring chamber (24x60mm). The 
slices were then treated with Daivonex to remove dust and impurities and were then 
rinsed with distilled water to remove remnants of the detergent. The slices were 
oxidised using UV-light/ozone (UVOCS, UVOCS, Montgomeryville, USA) for 10 
minutes. The slices were then placed in a plate (NUNC, Roskilde, Denmark) with 4 
rectangular wells, and 5 ml of 5 mg/ml sterile poly-D-lysine was added to each well. 
The slices were left in poly-D-lysine for 2-4 hours. While still in poly-D-lysine, the 
slices were sterilized for 20 minutes with UV-light. The slices were then washed with 
sterile water to remove the excess poly-D-lysine. Of the cell suspension gained from 
splitting the cells 1.6 ml was then diluted in 20 ml medium, and the resulting 
suspension divided evenly among the 4 wells. After three days, the cells were loaded 
with fura-2-AM as described below, using 5 ml medium for loading of cells with fura-
2 for each slice. The slices were the fitted to a polycarbonate chamber with a stainless 
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steel bottom (Ring and Tansø, unpublished data) and experiments were run in the 
plate reader.  
2.4.2 Treatment of polystyrene with a mixture of sulphuric acid and hydrogen 
peroxide 
The polystyrene sheets were cut to fit the measuring chamber (24x60mm). Nine parts 
concentrated sulphuric acid and one part 30% hydrogen peroxide was mixed and 
allowed to cool before the slices were placed in this solution for 10-30 minutes. This 
mixture is extremely corrosive and may explode in contact with organic compounds, 
and requires extreme care when handling. The slices were then washed with distilled 
water and placed in a plate with 4 rectangular wells. The slices were then coated with 
poly-D-lysine and the cells plated as described above. 
 
2.4.3 Treatment of glass coverslips with poly-D-lysine 
Rectangular (24x60mm) glass coverslips (Menzel, Germany) were immersed in 
concentrated nitric acid over night and then washed in Daivonex for one hour in an 
ultrasound bath (Bransonic 5510, Bransonic Ultrasound Corp., Danbury, CT). The 
detergent was removed by washing with distilled water and the coverslips were placed 
in 96% ethanol. The ethanol was burned off and the coverslips were placed in a plate 
with 4 rectangular wells. The coverslips were then coated with poly-D-lysine and the 
cells plated as described above. 
 
2.4.4 The commercially available plates: CellBind and Primaria 
In addition to treating the surface, two commercially available 96-well plates were 
tested; Corning CellBind® (Corning, Corning, NY) and Primaria® (Lev). Primaria is 
the plate used in the previous study (Dajas-Bailador et al. 2002). Both plates were 
used without pre-treatment. Of cell suspension obtained from splitting the cells 1 ml  
was added to 12 ml of medium and this suspension was divided to the 96-wells (125 
µl/well). 
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2.5 General procedure for experiments on the plate reader 
2.5.1 Solutions 
Medium for loading of cells with fura-2: 
4 µM Fura-2-AM (4 mg/ml) 
0.2 % Pluronic F-127 
1 mM Probenecid 
Culture medium for SH-SY5Y  
 
Medium for loading of cells with fluo-3: 
10 µM fluo-3-AM (11.5 mg/ml) 
0.2 % Pluronic F-127 
1 mM Probenecid 
Culture medium for SH-SY5Y  
 
Medium for deesterification: 
1 mM Probenecid 
Culture medium for SH-SY5Y 
 
Experimental buffer: 
140 mM NaCl 
15 mM Tris-HCl 
5 mM glucose 
3.5 mM KCl 
2 mM CaCl2
1.2 mM Na2HPO4 
1 mM MgSO4
Double distilled water 
 
This solution was bubbled with O2. The solution used in the injectors was placed in an 
exsiccator for 5 minutes. This was done to avoid bubbles forming during the 
experiments as the injected volumes were small and applied via tubing connected to 
syringes. 
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2.5.2 The plate reader 
 
 
 
Figure 2-5 A sketch of the imaging part of the plate reader. The image shows the principle 
measurement with fura-2, but the same applies to other probes. The numbers refer to wavelength of the 
filters. UV: Ultra violet. 
 
The BMG FluoStar Optima plate reader is controlled by a computer. It has to injectors 
that can be filled with experimental solutions; the temperature can also be set. Both 
the injectors and the lens are stationary, while the plate is moved around. Light is sent 
from an UV lamp through a excitation filter and a quartz fibre to the plate. The 
emitted light is sent through another quartz fibre to a filter, and then to a photo 
detector which sends an electrical signal to the computer for analysis. The filter wheel 
can switch between the filters to allow for ratiometric measurements (figure 2-5). 
 
2.5.3 Experimental procedure 
SH-SY5Y cells were cultured as previously described and the medium was changed 
to the medium for loading the cells with fura-2 or fluo-3, respectively. The detergent 
pluronic F-127 was used in the loading medium to increase the cellular uptake of the 
probe and the solubility of AM esters (Kao 1994). Probenecid was added, at 1 mM, as 
it inhibits the organic anion transporters and thus increases the amount of fura-2 or 
fluo-3 in the cytosol of the cells (Di Virgilio et al. 1990). For each well, 125 µl was 
used and the cells were placed in the incubator for 45-60 min. The medium for 
loading was then replaced with the medium for deesterification and put back in the 
incubator for 25-40 minutes. The plates were then removed from the incubator, and 
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the cells were washed once with experimental buffer before adding experimental 
buffer and antagonist to a total volume of 200 µl in each well. The agonist was diluted 
in experimental buffer and filled in the injector. The plate was then placed in the plate 
reader set at a temperature of 32 °C. The total measurement time for each well was 30 
seconds and 9 seconds for fura-2 and fluo-3, respectively. The agonist was injected 
under the computerised control of the plate reader after 8 seconds (fura-2) or 3 
seconds (fluo-3). The injection speed was 100µl/s, and the total injection volume was 
50 µM, except for experiments with K+-depolarization, where the injection volume 
was 100 µl.  
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2.6 Single cell imaging 
Round glass coverslips with a diameter of 18 mm were treated as described above for 
rectangular coverslips and transferred to a 12-well plate (NUNC, Roskilde, Denmark). 
Cells were split as described above, and 1 ml of the resulting suspension was 
transferred to each well. The cells were grown for 2-4 days before experiments.  
2.6.1 The imaging system 
 
 
Figure 2-6 Sketch of the imaging system. The system used for fura-2 is shown, but the same applies for 
other probes. The numbers refer to wavelength. UV: Ultra violet. 
 
The different components of the imaging system are shown in figure 2-6. The heart of 
the system is the microscope, Olympus IX70 (Olympus). The experiments were 
started so that the computer could control the monochromator (Polychrome II, TILL-
Photonics). The monochromator has a UV-lamp with a mirror that was moved by a 
computer controlled motor, allowing the alteration of wavelengths between 340 nm 
and 380 nm for fura-2. The light is led to the microscope by a quartz optical fibre and 
was reflected onto the cells by a dichroic mirror (i.e. a mirror that reflects certain 
wavelengths, but not other wavelengths). The emitted light passes through the 
dichroic mirror, as its wavelength is longer, and then through a filter. The filtered 
light was detected with a CCD (charged coupled device) video camera (Imago, 
advanced cooled imaging, TILL-photonics) coupled to a computer. 
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2.6.2 Single cell imaging of Ca2+-responses 
All experiments were run using fura-2. While still in the wells, the medium was 
changed to medium for loading the cells with fura-2, and the plate was placed back in 
the incubator for 45-60 minutes. For each well 1 ml was used. The medium for 
loading was then replaced with the medium for deesterification and put back in the 
incubator for 20-50 minutes. The coverslip with the cells was removed from the plate 
and transferred to a chamber with a stainless steel bottom and upper part made of 
Teflon. The chamber was assembled using screws. An O-ring sealed the upper part to 
the coverslip. The same experimental buffer that was used in the experiments with the 
plate reader was used in these experiments. The cells were washed twice with the 
experimental buffer. The volume of experimental buffer was fixed at 500 µM. The 
chamber with cells was then placed on the microscope. The excitation wavelengths 
were 340 and 380 nm and the emission was measured at 510 nm. The drugs were 
applied using a pipette. 
 
2.6.3 Single cell imaging using the membrane potential probe 
The coverslip with the cells were removed from the plate and transferred to a chamber 
similar to the one used for measurements of Ca2+, only smaller. This chamber was 
used to keep volumes small, as FMP is expensive. The same experimental buffer that 
was used for experiments with the plate reader was used for these experiments as 
well. The cells were washed twice with 100 µl of experimental buffer. 100 µl 
experimental buffer and 100 µl of the FMP solution was then added to the cells and 
the cells were left to equilibrate for 25-35 minutes. The chamber with cells was then 
placed on the microscope. The excitation wavelength was 500 nm and the emission 
was measured with a low pass filter with cut off at 540 nm (i.e. summing all emission 
with wavelength >540 nm). The drugs were applied to the cells using a pipette.  
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2.7 Astrocytes 
2.7.1 Culturing astrocytes 
Medium for astrocytes 
Penicillin/Streptomycin (GIBCO) 
15% Horse Serum 
Minimum Essential Medium (+ Earle’s + GlutaMax-I®) 
 
Astrocytes were kept in ampoules at -135 °C in regular medium with the addition of 
10% DMSO. The cells were previously prepared by dissection and culture from 
cerebella of 7 days old rat pups as previously described (Hertz et al. 1989). Primary 
cultures were grown for 21 days before being stored at -135 °C. The ampoules were 
removed from the freezer and left for 1 minute at room temperature before warming 
to 37 °C in a water bath. The content of each ampoule was then mixed with 12 ml 
medium, and the resulting suspension was plated out into a 96-well optical bottom 
plate (NUNC, Roskilde, Denmark).  The cells were then incubated at 36 °C in an 
atmosphere saturated with water vapour and with 5 % CO2. The medium was changed 
after one day to remove remnants of DMSO. The medium was changed every 3-4 
days. 
 
2.7.2 Experiments with astrocytes 
The solutions used were the same as for SH-SY5Y. The astrocytes were cultured for 
14-21 days before the experiments. The procedure used was as for SH-SY5Y except 
that the cells were loaded for 60 minutes and deesterified for 30 minutes.   
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2.8 Data analysis 
 
Raw data from the plate reader were analysed by subtracting a pre-measured 
background from the raw data. The ratios were then calculated by dividing the 
intensity at 340 nm by that at 380 nm. For further analysis the average of the first 4 
measurements were taken as the base line, and the average of the last 10 
measurements were taken as the peak intensity. The 4-parameter logistic equation 
(Hill equation) was then fitted to the data using GraphPad Prism version 4.00 for 
Windows, (GraphPad Software, San Diego California USA, www.graphpad.com).  
The equation is: Y = Bottom + (Top-Bottom) / (1 + 10^ ((LogEC50-X)*HillSlope)), 
where X is the logarithm of concentration and Y is the response. All the 
concentrations were first transformed to the logarithms of the concentration. The 
Bottom value was fixed at 0.  This equation corresponds to the Hill equation:  
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max +=  (Jenkinson 2002). In order to compare different data from 
different experiments, the data from these experiments were normalized prior to 
analysis as the maximal response varied between experiments. The resulting data 
were compared using the F test (Motulsky and Christopoulos 2003). A Hill coefficient 
(nH or HillSlope) different from unity is an indication of receptor kinetics more 
complex than first order kinetics id the receptor is studied directly (Barlow and Blake 
1989), however, in this thesis we measure down stream effects of receptor 
stimulation, and the Hill coefficient is taken simply as a parameter to get a good fit of 
the model. As the IC50 values obtained in this way have an asymmetrical confidence 
interval, the 95% confidence interval of the IC50 is quoted in stead of the Standard 
Error (SE) in the tables (Motulsky and Christopoulos 2003). The SE values are fairly 
small, so for convenience, the data will be shown as ± an average SE in the text. 
Average SE is taken as half the average difference between 95% confidence interval 
limits and the average. (i.e. 
4
)(())(( 50505050 lowerICICICupperIC −+− , where 
IC50(upper) and IC50(lower) is the upper and lower limit of the 95 % confidence 
interval). 
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3 RESULTS 
3.1 Single cell Ca2+-imaging of SH-SY5Y  
The initial objective was to establish a plate reader method to characterize the effects 
of drugs on responses to nicotine mediated by nAChR. The responses measured in a 
plate reader are the average of a large number of cells. In order to characterize the 
responses to nicotine and to determine the dynamics of the responses in single cells, 
single cell Ca2+-imaging was first performed on SH-SY5Y. Experiments were also 
made to determine the effects of some antagonists, to establish whether  
Ca2+-measurements could be used as an indicator of block of nAChR. A typical 
response to nicotine is shown below (figure 3-1). The response to nicotine shows a 
fast increase in [Ca2+]i  with a return to the base line within minutes. At 30 µM 
nicotine, the desensitation was significant and no sustained responses were possible. 
Larger doses gave faster desensitation, and a dose of 30-50 µM was judged as suitable 
for use with the plate reader. Single cell images of K+-depolarisation are shown in 
figure 3-4. 
  
0 100 200 300 400 500 600
0,0
0,1
0,2
0,3
0,4
0,5
F3
40
 / 
F3
80
sec
 
30 µM nicotine
Figure 3-1 Typical response to 30 µM nicotine in SH-SY5Y. F340/F380 fluorescent emmision ratio, 
where a rise indicate increased [Ca2+]i. The response is a fast rise followed by return to the baseline, 
due to desensitisation of nAChR. Cells were grown for three days on glass coverslips, and incubated 
with fura-2 for 45 minutes prior to use. Nicotine was added using a pipette.  
 Each line is the ratio from a single cell. 
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To see the effects of one known and one potential antagonist, these were added before 
nicotine in the single cell imaging experiments. Typical graphs for 20 µM memantine 
(a known antagonist) and procyclidine (a possible antagonist) are shown below. Both 
completely blocked the nicotine-induced responses (figures 3-2 and 3-3).  
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30 µM nicotine
20 µM memantine
Figure 3-2 Inhibition of nicotine induced [Ca2+]i-increase by 20 µM memantine. Addition of nicotine 
has no effect on ratio. Cells were grown for three days on glass coverslips, and incubated with fura-2 
for 45 minutes prior to use. Drugs added by pipette.  F340/F380 is fluorescent emmision ratio, where a 
rise indicate increased [Ca2+]i.  
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20 µM memantine
30 µM nicotine
Figure 3-3  Inhibition of nicotine induced [Ca2+]i-increase by 20 µM procyclidine. Addition of nicotine 
has no effect on ratio.  Cells were grown for three days on glass coverslips, and incubated with fura-2 
for 45 minutes prior to use. Drugs added by pipette. F340/F380 is fluorescent emmision ratio, where a 
rise indicate increased [Ca2+]i.  
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Figure 3-4 Ca2+-response of confluent SH-SY5Y cells to stimulation by depolarisation 50 mM K+. 
Transmission image (top left), fluorescence image before (top right) and after addition of 50 mM K+ 
(bottom left). Single cells may be obscure in confluent cultures. Increasing F340/F380 from blue to red. 
For comparison the kinetic data from this experiment are shown at bottom right. F340/F380 is 
fluorescent emmision ratio, where a rise indicates increase in [Ca2+]i.   
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3.2 Development of the screening method 
The initial experiments were aimed at developing a protocol for an efficient method 
with high signal to noise. As noted in the methods section, the choice of cell culture 
substrate is not trivial and a number of attempts were made in order to find a suitable 
substrate.  
 
Both systems using polystyrene sheets (i.e. home made coverslips), the sheets were 
oxidised to enable coating with poly-D-lysine. The oxidisation, however, resulted in 
unacceptable high levels of autofluorescence. The glass coverslips have very low  
autofluorescence, but the SH-SY5Y cells did not grow well on this substrate, and the 
substrate was thus discarded for use in the plate reader. In contrast, glass coverslips 
can be used for single cell imaging, where measurements are made in single cells and 
no advantage is gained if the cell layer is confluent. In the plate reader, however, a 
high density of cells gives a better signal to background margin, and therefore a more 
reliable result. The Primaria plates also gave an unacceptable high level of 
autofluorescence when using 340 nm and 380 nm excitation with fura-2. The novel 
CellBind plates had both an acceptable low level of autofluorescence, and supported a 
confluent growth of SH-SY5Y. Thus CellBind plates were chosen for further 
experiments.  
 
Using SH-SY5Y cells cultured on CellBind a dose-respose curve for nicotine was 
obtained (figure 3-5). The maximum response was obtained with 50 µM nicotine. At 
higher concentrations of nicotine the response was lower, probably as a result of the 
desensitization of the nAChRs. An EC50 of 16.8 µM ± 1.5 µM was obtained by best-
fit of the Hill equation (see methods). In further experiments 50 µM nicotine was 
therefore used. Initially only 48 wells were run in each experiment, resulting in a total 
recording time of 25 minutes. Further testing and analysis found no difference in 
running 48 or 96 wells at a time in this system, even though the last well was run 50 
minutes after the first. 96 wells were therefore run at a time as this increased the 
number of parallels. Typical responses from a single experiment are shown in figure 
3-6.  
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Figure 3-5 Dose-response curve for calcium responses of SH-SY5Y cells to nicotine.  
Cells grown for three days on a CellBind multiwell plates and incubated with fura-2 for 45 minutes. 
Average Ca2+-response ± SEM are shown at each concentration. F340/F380 is fluorescent emission 
ratio, where a rise indicate increased [Ca2+]i.  n=8. 
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Figure 3-6a Typical “raw data” for single well responses for 48 of the 96 wells in a dose response 
experiment for calcium responses of SH-SY5Y cells to nicotine. Cells were grown for three days on a 
CellBind multiwell plate and incubated with fura-2 for 45 minutes. The red line is fluorescence for 
excitation at 340 nm (F340), the blue line at 380 nm (F380). The increase of F340 and decrease of 
F380 is a clear indication of intracellular Ca2+ rise. Columns 1-6 (from left) are dose-responses to 
nicotine alone, while columns 7-12 is a dose-response with 1 µM trihexphenidyl, an anticholinergic 
Parkinson drug, added. Doses were (left to right) 0 µM, 5 µM, 10 µM, 20 µM, 30 µM, and 50 µM.  
The same doses were used with trihexphenidyl in the bath.  
 
 
 
Figure3-6b Typical ratios for single well responses for 48 of the 96 wells in a dose response experiment 
for calcium responses of SH-SY5Y cells to nicotine. These are the ratios to that corresponds to the data 
of figure 3-6a. Cells were grown for three days on a CellBind multiwell plate and incubated with fura-2 
for 45 minutes. Columns 1-6 (from left) are dose-responses to nicotine alone, while columns 7-12 is a 
dose-response with 1 µM trihexphenidyl, an anticholinergic Parkinson drug, added. Doses were (left to 
right) 0 µM, 5 µM, 10 µM, 20 µM, 30 µM, and 50 µM.  The same doses were used with trihexphenidyl 
in the bath.  
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3.3 Determination of IC50 for inhibition of nicotine induced  
Ca2+-responses in SH-SY5Y 
3.3.1 Drugs that block the NMDA-receptor 
 
Name logIC50 ±SE 
 
IC50 95 % Confidence 
interval of IC50
Hill coefficient 
±SE  
Biperiden  0.19 ± 0.03 1.56 µM 1.36 - 1.79 µM -1.49 ± 0.13 
Caramiphen -0.49 ± 0.03 0.323 µM 0.287 - 0.363 µM -1.22 ± 0.08 
(±)-Gacyclidine -0.53 ± 0.04 0.296 µM 0.247 - 0.355 µM -1.51 ± 0.16 
(-)-Gacyclidine -0.78 ± 0.03 0.163 µM 0.139 - 0.190 µM -1.34 ± 0.11 
Memantine  0.45 ± 0.04 2.85 µM 2.37 - 3.41µM -1.16 ± 0.12 
(+)MK-801  0.25 ± 0.06 1.80 µM 1.40 - 2.31 µM -1,31 ± 0.16  
Procyclidine  0.14 ± 0.04 1.38 µM 1.14 - 1.66 µM -1.41 ± 0.17 
Trihexphenidyl -0.13 ± 0.04 0.75 µM 0.627 - 0.895 µM -1.34 ± 0.14 
 
Table 3-1 IC50 values for block of nAChR-responses by different NMDA-R blockers. All values are 
obtained by best-fit of the Hill-equation as described in the methods section. Values are pooled data 
from at least two independent experiments. n=6-8.  
 
SH-SY5Y cells were cultured for 3 days in CellBind plates, and the [Ca2+]i–responses 
were obtained using 50 µM nicotine. The logIC50, IC50 and Hill coefficient values 
were obtained from best-fit of the Hill equation, as described in the data analysis, 
section from pooled data of at least two independent experiments for each drug.  
The IC50 value was 1.56 µM ± 0.11 µM for biperiden, 0.323 µM ± 0.019 µM for 
caramiphen, 0.296 µM ± 0.027µM for racemic gacyclidine, 0.163 µM ± 0.013µM for  
(-)-gacycldine, 2.85 µM  ± 0.28 µM for memantine, 1.80 µM ± 0.23µM for MK-801,  
1.38 µM ± 0.13µM for procyclidine and 0.75 ± 0.07 µM for trihexphenidyl. For the 
anticholinergic Parkinson drugs, trihexphenidyl was significantly more potent than 
procyclidine and biperiden, while there was no significant difference between 
biperiden and trihexpenidyl. In experiments in a single plate, no significant difference 
was found between racemic and (-)-gacyclidine, although further studies indicate the 
(-)-gacyclidine may be slightly more potent. The results are shown in table 3-1 and 
inhibition curves are shown in figure 3-7. 
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Figure 3-7 Best-fit curves for inhibition of nicotine induced Ca2+-responses in SH-SY5Y. Cells were 
grown for three days on CellBind multiwell plates and incubated with fura-2 for 45 minutes. Average 
Ca2+-response ± SEM are shown at each concentration. The response is shown in % of maximum 
response.  n=6-8
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3.3.2 Novel bis-quarternary pyridine compounds 
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Figure 3-8 Inhibition of nicotine (50 µM) induced Ca2+-responses in the neuroblatoma cell line  
SH-SY5Y by novel bis-quarternary pyridine compounds. Cells were grown for 3 days on Cellbind 
multiwell plates and incubated with fura-2 for 45 minutes. All drugs were tested were at 100 µM. 
Mecamylamine is a known neuronal nAChR blocker and was used as positive control. Average  
Ca2+-response with SEM are shown for each drug. All responses were normalised to the response to 
nicotine without inhibitor (control) taken as 100%.  n=8. ** p<0.01, ANOVA with Dunnett’s post hoc 
test. 
 
In an initial experiment all the compounds, with chain length from 1 to 10 carbon 
atoms, were tested at a high concentration to screen for blocking activity. SH-SY5Y 
cells were cultured for 3 days, and the Ca2+–responses were obtained using 50 µM 
nicotine. The compounds with chain lengths C1-C3 did not show any inhibition of  
nAChR-responses (figure 3-8), and their IC50 values were therefore not determined. 
The logIC50, IC50 and Hill coefficient values were obtained from the Hill equation as 
described in the data analysis section from pooled data of at least two independent 
experiments, except for MB444 where only data from a single experiment was used. 
The block decreases for increasing chain length, with an fairly linear relationship 
between the logIC50 and the chain length. The IC50 values ranged form 439µM ± 49 
µM for MB444 (C4) to 1.68 µM ±0.13 for SH63 (C10).  The results for the blocking 
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action on neuronal nAChR are summarized in table 3-2. Inhibition curves for these 
compounds are shown in figure 3-9. 
 
 
Name 
Chainlength logIC50 ±SE 
 
IC50 95 % Confidence 
interval of IC50
Hill coefficient 
±SE  
MB444 C4 2.73±0.04  539 µM 447 - 650 µM -1.81±0.26 
MB442 C5 1.99±0.04 98.0 µM 82.1 - 116.9 µM -2.1±0.4 
SH62 C6 1.46±0.04 28.5 µM 24.3 - 33.5 µM -1.88±0.24 
SH64 C7 1.57±0.05 37.2 µM 30.0 -  46.1 µM -1.8±0.3 
MB505 C8 1.24±0.03 17.2 µM 14.8 - 20.2 µM -1.74±0.22 
SH65 C9 0.62±0.04 4.20 µM 3.56 - 4.96 µM -1.66±0.20 
SH63 C10 0.22±0.03 1.68 µM 1.44 - 1.95 µM -1.28±0.09 
 
Table 3-2 IC50 values for block of nAChR-responses by novel bis-quarternary pyridine compounds. All 
values are obtained by best-fit of the Hill-equation as described in the methods section. Values are 
pooled data from at least two independent experiments, except for MB444. n=6-8.   
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Figure 3-9 Best-fit curves for inhibition of nicotine induced Ca2+-responses in SH-SY5Y. Cells were 
grown for three days on CellBind multiwell plates and incubated with fura-2 for 45 minutes. Average 
Ca2+-response ± SEM are shown at each concentration. The response is shown in % of maximum 
response. Data from at least two experiment for all compounds except MB444 (C4). n=6-8. 
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3.4 Testing the use dependence of the block of the nicotine induced 
Ca2+-responses by certain drugs 
 
 IC50 at 25 µM nicotine  
± average SE 
IC50 at 250 µM 
nicotine   
± average SE 
Ratio of IC50s 
(25µM/250µM) 
p-value for 
difference 
Biperiden 1.47 ±0.21 µM 0.66 ±0.10 µM   2.81 0.0002 
(±)-gacyclidine 0.31 ±0.07 µM 0.16± 0.04 µM 1.82 0.059 n.s 
(-)-gacyclidine 0.23 ±0.04 µM 0.083 ±0.011 µM 2.82 0.0001 
Mecamylamine 0.025 ±0.007 µM 0.023 ±0.03 µM 1.1 0.76 n.s. 
Memantine 3.2 ±0.9 µM 1.05  ±0.15 µM 3.05 0.0021 
MK-801 2.4 ±0.3 µM 1.8 ±0.3 µM 1.33 0.31 n.s. 
Procyclidine 1.6 ±0.4 µM 0.98 ±0.16 µM 1.70 0.083 n.s. 
Trihexphenidyl 1.11 ±0.20 µM 0.50 ±0.05 µM 2.19 0.0002  
SH63 (C10) 3.2 ±0.8 µM 1.7 ±0.3 µM 1.77 0.044 
(+)-tubocurarine 0.66 ±0.16 µM 0.64 ±0.06 µM 1.03 0.92 n.s. 
Table 3-1 IC50-values of inhibitors of nAChR-responses in SH-SY5Y with 25 µM and 250 µM 
nicotine. Cells were grown for three days on CellBind multiwell plates and incubated with fura-2 for 45 
minutes. Data were obtained by best-fit of the Hill equation as described in methods. All data shown ± 
average SE. P-values are from F tests. n.s.: not significant. 
 
The manner of block is physiologically and clinically relevant. The use-dependence of 
an inhibitor is important since one wishes that the inhibition should be low for normal 
physiological conditions whereas the block should be significant for conditions of 
excess stimulation of nAChRs, such as is expected when the AChE is inhibited (e.g. 
in organophosphate poisoning). We were interested in testing whether the drugs 
showed a use dependence in their block of the nAChR, i.e. whether the degree of 
activation of the receptors influenced the value of the IC50. In order to test this, the 
IC50 of the drugs were determined for two different concentrations of nicotine; 25 µM 
and 250 µM (table 3-3). These concentrations were chosen because both give 
measurable Ca2+-responses to nicotine and are significantly different doses. SH-SY5Y 
cultured as described above for 3 days were loaded with fura-2 and experiments run 
as described above. If the IC50-values were significantly (p < 0.05) smaller at 250 µM 
Results 
than at 25 µM the result was taken as a indication of use-dependence. In brief, 
biperiden, (-)-gacyclidine, memantine, trihexphenidyl and SH63 (C10) showed 
signinficant use-dependence, while mecamylamine, MK-801, and (+)-tubocurarine 
did not. Procyclidine and racemic gacyclidine did not reach significance, but this may 
be due to insensitivity of the method. The graphs for SH63, procyclidine and 
(+)tubocurare are shown below (figure 3-10).  
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Figure 3-10 Inhibition curves with high (250 µM) and low (25 µM) nicotine for SH63, procyclidine 
and (+)-tubocurarine. F340/F380 is fluorescent emission ratio, where a rise indicate increased [Ca2+]i. 
Cells were grown for three days on CellBind multiwell plates and incubated with fura-2 for 45 minutes. 
Average Ca2+-response ± SEM are shown at each concentration. n=8.   
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3.5 Voltage dependence of block of nAChR-responses 
Similar to use dependence, the voltage dependence is of interest since one wants a 
greater degree of block when the neurons are depolarized, whereas there is no use for 
inhibition when the neurons are at the resting level. The voltage dependence of the 
block of nAChRs by procyclidine, memantine and MK-801 were tested by changing 
the concentration of K+ in the experimental buffer to 2.5 mM (low membrane 
potential) and to 10 mM (high membrane potential) and then obtaining inhibition 
curves as described above. For procyclidine the IC50 values at low and high membrane 
potential were 1.26 ± 0.07 µM and 1.05 ±0 .06 µM, respectively. For memantine the 
IC50 values were 2.00 ± 0.21 µM and 1.35 ± 0.18 µM, respectively. The differences 
were significant for both procyclidine and memantine (p < 0.037). For MK-801 the 
IC50 values were 1.29 ± 0.11 µM and 1.07 ± 0.08 µM, respectively. This different was 
not significant (p < 0.118). There was no significant difference between the Hill 
slopes for either experiment. The inhibition curves for these experiments are shown in 
figure 3-11. 
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Figure 3-11 Inhibition curves with high (10 mM K+) and low (2.5 mM K+) for memantine, procyclidine 
and MK-801. F340/F380 is fluorescent emission ratio, where a rise indicate increased [Ca2+]i. Cells 
were grown for three days on CellBind multiwell plates and incubated with fura-2 for 45 minutes. 
Average [Ca2+]i at each concentration shown ± SEM.  n=6-8. 
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3.6 Screening of effects on voltage-operated Ca2+-channels  
 
All the drugs tested blocked nicotine induced Ca2+-responses. A part of this block is 
expected to be due to direct block of influx through neuronal nAChR. Nevertheless, a 
significant part of the Ca2+-response is a downstream effect due to influx through 
voltage operated Ca2+-channels (VOCC), since depolarisation due to opening of the 
channels activates these channels (Dajas-Bailador et al. 2002). It was therefore 
relevant to test whether the drugs would block depolarisation induced Ca2+-responses. 
SH-SY5Y cells cultured for 3 days as described above. The Ca2+-response to 
depolarisation was determined by stimulation with 25 mM – 100 mM K+ (figure 3-12) 
and 50 mM was chosen as a suitable concentration. 30 µM verapamil, a well known 
blocker of VOCC, was used as a positive control (Kohlhardt 1975).  
 
 
Figure3-12a. Typical “raw data” for single well responses for 48 of the 96 wells in a dose response 
experiment for calcium responses of SH-SY5Y cells to K+. Cells were grown for three days on a 
CellBind multiwell plate and incubated with fura-2 for 45 minutes. Red line is fluorescence at 340 nm 
(F340), blue line at 380 nm (F380). The increase of F340 and decrease of F380 is a clear indication of 
intracellular Ca2+ rise. Doses of K+ were (left to right) 0 mM, 25 mM, 30 mM, 35 mM 40 mM, 45 mM, 
50 mM, 60 mM, 70 mM, 80 mM, 90 mM, and 100 mM.  
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Figure 3-12b Typical ratios for single well responses for 48 of the 96 wells in a dose response 
experiment for calcium responses of SH-SY5Y cells to K+. Cells were grown for three days on a 
CellBind multiwell plate and incubated with fura-2 for 45 minutes. These are the ratios to that 
corresponds to the data of figure 3-12a Doses were (left to right) 0 mM, 25 mM, 30 mM, 35 mM 40 
mM, 45 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, and 100 mM.  
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3.6.1 Effect of NMDA-receptor inhibitors on K+ induced Ca2+-responses 
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Figure 3-13 Inhibition of K+ (50 mM) induced Ca2+-responses in the neuroblatoma cell line SH-SY5Y 
by drugs that block the NMDA-R. Cells were grown for 3 days on a Cellbind multiwell plate and 
incubated with fura-2 for 45 minutes. Verapamil is a known blocker of VOCC and is used as positive 
control. Average Ca2+-response with SEM are shown for each drug.  All responses were normalised to 
the response to K+ without inhibitor (control) taken as 100%.  n=8 *p<0.05 ** p<0.01, ANOVA with 
Dunnett’s post hoc test. 
 
All the drugs were tested at concentrations high above those needed to block nAChRs. 
Only the anti-cholinergic Parkinson drugs and memantine significantly blocked the 
direct depolarisation response. The NMDA-R antagonists gacyclidine and MK-801 
did not show any significant block at the concentrations tested (figure 3-Figure 13).  
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3.6.2 Lack of effect of by novel bis-quarternary pyridine compounds on K+-
induced Ca2+-responses 
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Figure 3-14 Inhibition of K+ (50 mM) induced Ca2+-responses in the neuroblastoma cell line SH-SY5Y 
by novel bis-quarternary  pyridine compounds. Cells were grown for 3 days ona Cellbind multiwell 
plate and incubated with fura-2 for 45 minutes. Verapamil is a known blocker of VOCC and is used as 
positive control. Average Ca2+-response with SEM are shown for each drug. ll responses were 
normalised to the response to K+ without inhibitor (control) taken as 100%.  n=8. ** p<0.01, ANOVA 
with Dunnett’s post hoc test. 
 
None of the novel muscle nAChR blockers showed any block of the response at the 
concentrations tested (figure 3-14). Here the compounds with chain length from 5 to 
10 carbon atoms were tested at 100 µM, which is the concentration used as the upper 
limit for screening for effects on the muscle nAChR (John Tattersall, personal 
communication). The compounds with chain length from 1 to 4 carbon atoms showed 
no significant block at nAChR at 100 µM, and therefore testing for effects on VOCC 
was not relevant. Nevertheless, they were then tested for a possible effect at an even 
higher concentration (250 µM). 
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3.6.3 Determination of IC50-values for K+-induced Ca2+-increase for some 
NMDA-receptor blockers 
For the NMDA-R blockers showing block of K+-induced Ca2+-increase in the 
screening, IC50-values were determined by best-fit of the Hill equation. Errors are 
given as 95% confidence intervals. For memantine the IC50 value was 64 µM 
(31-134 µM). For biperiden, procyclidine and trihexphenidyl the IC50 values were  
29 µM (22-37 µM), 11.4 µM (8.4-15.5 µM) and 22 µM (16-31 µM), respectively.  
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3.7 Screening for effects on muscarinic acetylcholine receptors 
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Figure 3-15 Screening of effects on carbachol induced Ca -responses in the neuroblastoma cell line 
SH-SY5Y by drugs that block the NMDA-R. Cells were grown for 3 days on a Cellbind multiwell 
plate and incubated with fura-2 for 45 minutes. Atropin, a known mAChR antagonist, is used as 
positive control. The average Ca -response with SEM is shown for each drug. The responses were 
normalised to the response to carbachol without inhibitor (control) taken as 100%.  n=8. *p<0.05 
2+
2+
** 
p<0.01, ANOVA with Dunnett’s post hoc test. 
 
The main effects of nerve gas poisoning is attributed to the effects on mAChRs. For 
drugs to be used against organophosphate poisoning it is therefore relevant to test 
whether they block the mAchRs of SH-SY5Y. SH-SY5Y cultured for 3 days, were 
loaded with fluo-3 for these experiments. Fluo-3 offers a higher temporal resolution in 
the plate reader, which is needed in order to observe these responses properly.  
Carbachol is an agonist of the mAChR and 5 µM of carbachol was used. Atropin is a 
classical mAChR antagonist and was the positive control in this experiment. The 
results are shown in figure 3-15. The only drugs that gave significant block were 
verapamil, La3+ and caramiphen. Verapamil blocks VOCC, while La3+ blocks  Ca2+-
pathways, including ,non specific cation channels. Caramiphen is a known mAChR-
antagonist (Hudkins and DeHaven-Hudkins 1991) and atropine is the positive control.  
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3.8 Screening for effects of NMDA-R blockers on purinergic 
receptors 
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Figure 3-16 Lack of effect by NMDA-R inhibitors on ATP-induced (50 µM) Ca2+-responses in 
astrocytes by drugs that block the NMDA-R. Cells were grown for 3 days on NUNC multiwell plates 
and incubated with fura-2 for 1 hour. Suramine is a known P2-receptor antagonist and is used as 
positive control. Average Ca2+-response with SEM are shown for each drug. The responses were 
normalised to the response to ATP without inhibitor (control) taken as 100%.  n=8.  ** p<0.01, 
ANOVA with Dunnett’s post hoc test. 
 
There were no significant effects of the NMDA-R inhibitors on ATP-induced  
Ca2+-responses in rat cerebellar astrocytes (figure 3-16). 100µM suramin, a blocker of 
both P2X and P2Y-receptors, is the positive control. The residual response for 
suramin is most likely due to mechanical stimulation of the astrocytes.   
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3.9 Effects on SH-SY5Y response to nicotine by procyclidine and 
SH63 on membrane potential 
Nicotine activates nAChR, and the non-specific increase in cation permeability gives 
rise to membrane depolarisation. As an additional check for the effects of inhibitor on 
the neuronal nAChRs, we investigated if nicotine induced changes in single cell 
responses to membrane potential. The anticholinergic Parkinson drug procyclidine 
and the bis-quarternary pyridine compund SH63 were tested for their ability to block 
this reponse. Both procylidine and SH63 blocked the nicotine induced increase in 
membrane potential. K+ was used as a positive control in each experiment (figures 
 3-17 – 3-19).  
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Figure 3-17 Changes in membrane potential in response to 50 µM nicotine and 100 mM K+ as 
measured by FMP. The fast increase and subsequent desensitisation after the addition of nicotine is a 
typical feature of nAChR responses. Cells were grown on glass coverslips for 3 days and incubated 
with FMP for 30 minutes before the experiment. Fluorescence scale is in arbritary units. 100 mM K+ 
represents maximal depolarisation. 
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Figure 3-18 Changes in membrane potential in response to nicotine and K+ after preincubation with  
5 µM procyclidine as measured by FMP. Cells were grown on glass coverslips for 3 days and 
incubated with FMP for 30 minutes before the experiment. Fluorescence scale is in arbritary units. 100 
mM K+ represents maximal depolarisation. 
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Figure 3-19 Response to nicotine and K+ after after preincubation with 100 SH-63 as measured by 
FMP. Cells were grown on glass coverslips for 3 days and incubated with FMP for 30 minutes before 
the experiment. Fluorescence scale is in arbritary units. 100 mM K+ represents maximal depolarisation. 
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4 DISCUSSION 
 
71 
4.1 Evaluation of the method 
The main difference between single-cell imaging and measurements with a plate 
reader is that the plate reader gives much less spatial and temporal resolution than 
single-cell imaging. Therefore, transient changes in the Ca2+-response are harder to 
observe with a plate reader. The plate reader, however, allows for automated 
measurement of many wells, and thus testing of more compounds and more parallels 
on the same batch of cells. The variability between cells in single-cell imaging will 
disappear in the plate reader, where each measurement represents the average of 
response of a large number of cells. As a result of this, the well-to-well varibility is 
smaller than that between cells in single cell experiments.  
 
As seen from the single cell data, desensitasation of the nAChR is a significant issue 
even at 30 µM nicotine. This differs from previous data, where a sustained response 
over 10 minutes was reported after application of 30 µM nicotine (Dajas-Bailador et 
al. 2002). This difference may relate to the higher amounts of dye used in those 
experiments, or to some difference in the differentiation, subclone of SH-SY5Y or 
culturing conditions of the SH-SY5Y cell line. 
 
The desensitation is most likely responsible for our observation that the response 
measured in the plate reader with 50 µM nicotine was slightly greater than the 
response with 100 µM. With averaged responses, i.e. the cells are not synchronized, a 
large but faster declining response may appear smaller than a smaller slower declining 
response. The EC50 value obtained from best fit of the Hill equation is probably 
affected by this. The EC50 value of for nicotine stimulated responses on nAChR is 
16.8 µM ± 1.5 µM is considerably lower than the value of 43 µM determined by 
whole-cell patch-clamp (Sokolova et al. 2005). This may in part be because 
desensitasation leads to an underestimate of the maximum response (Ymax), and 
therefore to an underestimate of the value giving half the maximum response (EC50). 
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The effects of desensitisation on the EC50 value for nicotine are not relevant to the 
determination of the IC50 values of the drugs, since in the latter case all experiments 
were made at the same concentration of nicotine, 50 µM. It should be noted that the 
method does not discriminate between effects of the drugs on desensitisation and 
effects on channel gating or permeation. A decreased Ca2+ response could, in 
principle; result from an effect where the drug does not block the channel but instead 
increases the desensitisation rate. The details of the molecular mechanisms of the 
nAChR responses, however, were not the aim of this study. For such studies, single 
cell imaging and patch-clamp data are more appropriate. 
 
There are some concerns in running experiments with fluorescent dyes over a time 
span of nearly an hour. Extrusion of the dye from the cell may be a significant 
problem. Therefore, a protocol using fluo-3 would not allow this type of experiment. 
Fluo-3 is a non-ratiometric dye and a slow drift in the amount of dye would give 
artefactual changes. Fura-2 is mainly extruded from the cells by the organic anion 
transporters (Di Virgilio et al. 1990). It has been reported that low temperature 
(Malgaroli et al. 1987) or probenecid, an inhibitor of organic anion transporters (Di 
Virgilio et al. 1990), may increase the cytosolic concentration of fura-2 and inhibit its 
extrusion. For this reason, probenecid was included in all experimental solutions and 
the temperature was set at 32 °C. It was easier to keep a reproducible temperature at a 
slightly higher value than room temperature, as the room temperature is not constant 
in the lab. The other main concern is the transport of probe into intracellular 
compartments like mitochondria or the ER. There is no simple way of inhibiting this 
compartmentalisation, although lower temperature slows uptake intracellular 
compartments. For these reasons, only 48 wells were initially run, but as there were 
no significant differences between experiments with 48 and 96 wells, 96 well were 
used in the final method.  
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4.1.1 Validating the method  
The method uses the indirect consequences of nAChr channel opening and cell 
membrane depolarisartion. One concern was that the block obtained from the drugs 
was a block of Ca2+-responses downstream to the activation of nAChr, and not an 
indication of the block of nAChR themselves. The nAChr activation results in a rise 
in [Ca2+]i which is partly due to influx of Ca2+ through the nAChr, but is also due to a 
secondary rise in [Ca2+]i which comes as a consequences of Ca2+ and Na+ influx. In 
Ca2+ responses of excitable as well as inexcitable cells there are generally a number of 
phases of calciunm change, starting with a fast peak in Ca2+. For example, IP3 and 
CICR (see section 1.2.2) mediated responses are transient phenomena which typically 
give a peak in Ca2+  that starts already after fractions of a second and lasts for a few 
seconds.  In the method used here we intentionally measure later responses,  more 
than 10 seconds after nicotine stimulation, that correspond to the sustained phase of 
the response to nicotine, when the transient peak has already decayed (Berridge and 
Bootman 1998). 
 
To test for effects of drugs on the non-desensitizing voltage operated calcium 
channels (VOCC), K+ was used to depolarise the cells and drugs were used at values 
much higher than their IC50 to screen for effects on the depolarisation induced calcium 
influx. No block of the K+-induced calcium influx was seen at relevant concentrations 
consistent with the interpretation that the block seen is that of the nAChR and not of 
the downstream recruitment due to the depolarisation. Memantine has previously been 
shown to block nAChR with IC50 values from 0.3 to 7 µM, depending on the subtype 
and tissue model used. Mematine was also shown to block the different nAChR in a 
use-dependent and voltage-dependent manner (Buisson and Bertrand 1998; Maskell et 
al. 2003; Aracava et al. 2005). It is therefore a suitable control for the use-dependent 
and voltage dependent block of nAChR. The IC50 value of 2.85 µM obtained for 
memantine is in the middle of the range of the previously reported data. In addition, 
the method reproduced the use-dependent and voltage-dependent block of nAChr by 
memantine, a result which demonstrates the usefulness and validity of the method.  
 
To further test the consistency of the results, a single cell imaging experiment was run 
to test for block of nicotine stimulated depolarisation with the aid of the membrane 
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potential probe. This measurement is mainly dependent on Na+-influx through nAChr 
and not on secondary recruitment of intracellular Ca2+. Procyclidine blocked the 
nicotine-induced change in membrane potential consistent with the conclusions, from 
the measurements with fura-2, that anticholinegic Parkinson drugs block the nAChr. It 
may be noted that FMP is not as suitable as fura-2 in plate reader experiments because 
it is not ratiometric and the signal changes with time. 
 
4.1.2 Further improvement of the method 
The method is well suited for screening drugs for general effects on nAChR. A 
limitation with the cell model used here, and similarly with any cell line expressing 
more than one subtype of nAChR, is that the protocol used does not discriminate 
between the different subtypes of nAChRs. Currently, no method exists to screen for 
effects on different subtypes. The most frequently used method for studying single 
subtypes of nAChRs is hetrologous expression in oocytes or in cell lines (Buisson and 
Bertrand 1998; Kishi and Steinbach 2006). Although oocytes are not suitable for 
screening, a cell line model would be suitable if the nAChR is stably expressed. In 
general this is not easily attainable. Instead, one possible approach could be to attempt 
to block the specific receptors with selective blockers. The main nAChRs in SH-
SY5Y are α3β2 and α7-receptors (Dajas-Bailador et al. 2002). Therefore, selective 
blockers for these receptors may be useful to block out the contribution of either 
receptor, e.g. using α-bungraotoxin to block α7-receptors or α-conotoxin MII to block 
α3β2-receptors (Dajas-Bailador et al. 2002). Extension of the method in this direction 
will be attempted in future work but was not attainable within the scope of the present 
thesis. 
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4.2 Anticholinergic Parkinson drugs 
One of the objectives of the thesis was to determine the possible inhibition of nAChRs 
by anticholinergic Parkinson drugs. Trihexphenidyl was the most potent of the anti-
cholinergic Parkinson drugs at the nAChR-response and about twice as potent as 
biperiden and procyclidine, which are approximately equipotent. This does not 
correlate well with their potencies at the NMDA-R, where procylidine is about 15 
times more potent (i.e. has 15 times lower IC50) than biperiden and trihexphenidyl. 
Procyclidine is about twice as potent at nAChR as at NMDA-R, while biperiden and 
trihexphenidyl are about 30 and 60 times, respectively, more potent on nAChR than 
on NMDA-R. Even though procyclidine is the least potent of the drugs on mAChRs, 
it is still about 20 times more potent on the mAChR than on the nAChR.  Biperiden 
and trihexphenidyl are approximately 180 and 30 times more potent on mAChR than 
on nAChR (Syvälahti et al. 1988). All these drugs also blocked VOCC, but at 
concentrations at least 10 times higher than the ones needed to block nAChR, and the 
block of nAChR seen is therefore not significantly affected by block of VOCC. 
However, biperiden and trihexphenidyl blocks the NMDA-R with potencies similar to 
that of VOCC (Ring and Tansø, unpublished data). To summarise, the relative 
potencies for block of mAChR are biperiden > trihexphenidyl > procyclidine 
(Syvälahti et al. 1988), for nAChR trihexphenidyl > procyclidine ≈ biperiden and for 
NMDA-R procyclidine >> biperiden ≈ trihexphenidyl.  
 
4.2.1 Use- and voltage-dependence 
A use dependent manner of block ideally allows for the normal activity of the 
receptor, while blocking the higher activity of receptors. This may be relevant for 
conditions like ischemic brain damage (excessive glutamate receptor activation) and 
brain seizures due to organophosphate poisoning (excessive cholinergic activation). 
The picture is complicated by the fact that some manner of use-dependence, in 
particular open-channel block, can inhibit the desensitsation of the receptor, and thus 
increase the total activity of the receptor (Alkondon and Albuquerque 1989). Voltage 
dependent block may be seen as a variant of use dependence, where the overall 
activity of the cell, as set by its membrane potential, controls the blocking activity of 
the inhibitor. Both biperiden and trihexphenidyl showed a significant use dependent 
block. Procyclidine did not show significant use dependence, but it showed voltage 
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dependence. As the structure of these anticholinergic Parkinson drugs are very 
similar, it is diffucult to see that one would block in a non-use dependent manner, 
while the others do. The negative result for procyclidine may be attributed to a lack of 
sensitivity of the method. In comparison, the block of nAChR by procyclidine was 
voltage dependent, and biperiden and trihexphenidyl were not tested. It is probable  
that all the anticholinergic Parkinson drugs block the nAChR in a use and voltage 
dependent manner, although further experiments are needed to clarify this. 
 
4.2.2 Pharmacokinetic aspects of block by anticholinergic Parkinson drugs 
It would be valuable to extend the present work with measurement of the brain uptake 
of the drugs, since these data are not found in the literature, except for biperiden. 
Nevertheless, from the available pharmacokinetic data, we may try to estimate the 
brain concentrations of the anticholinergic Parkinson drugs. The plasma concentration 
of the drugs after intravenous injection of a single dose may be calculated from the 
equation:  
)/(
)/()/(
kgLV
kgmoldoseLmolC
d
= , where Vd is the apparent volume of distribution (Benet 
et al. 1995). Using this equation and the values given by Brocks (1999) (for values, 
see section 1.7.1), the plasma concentration of biperiden corresponding to the ED50 
against soman-posioning in rat (Shih et al. 1999) after 5 and 40 minutes are 12.0 nM 
and 2.55 µM, respectively. This is assuming that the Vd are the same in rat and 
human. Since the concentrations in the brain are 10 times the plasma concentration  
(Yokogawa et al. 1992), the corresponding brain concentrations are 0.12 µM and 25.5 
µM. There is general agreement that block of mAChR is the dominant mechanism for 
stopping seizures 5 minutes after soman exposure. The concentration after 5 minutes 
is therefore expected to be of a magnitude consistent with the IC50 value for block of 
mAChR. This is in agreement with the value of 0.12 µM estimated above. This value 
is also a factor of 10 below the IC50 of biperiden on nAChR-responses and a factor 
400 below the IC50 for NMDA-R (Ring and Tansø, unpublished data), also consitent 
with the consensus that after 5 minutes only the mAChR are involved.  
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It is reasonable to assume that the concentrations of the drugs in the brain required to 
stop seizures are proportional to the respective IC50 values on mAChR. As no data 
relating to the partition of procyclidine or trihexphenidyl is available, these have to be 
estimated. If we assume the brain concentration calculated above for biperiden and 
use the IC50 of biperiden at mAChR (Syvälahti et al. 1988) we can calculate the ratio 
between the brain concentration and the IC50 for biperiden:  
3.14
0084.0
12.0
50
===
µM
µM
IC
Cratio brain  
If this ratio is valid also for other anti-muscarinic drugs, e.g. procyclidine, then the 
brain concentration of procyclidine 5 minutes after soman poisoning is: 
µMµMICratioCbrain 0.1070.03.1450 =⋅=⋅=  
If we assume that the concentration in the brain is proportional to the dose given then 
the concentration corresponding to the ED50 after 40 minutes (Shih et al. 1999) is  
µMµM
kgmg
kgmgC
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These calculations estimate the brain concentrations of procyclidine corresponding to 
ED50 against soman-induced seizures 5 and 40 minutes after soman-poisoning to be 
1.0 µM and 8.8 µM, respectively. If we do the same calculations for trihexphenidyl 
the corresponding values are 0.4 µM and 14 µM.  
 
With the above assumptions, we may now conclude that, the concentrations 40 
minutes after soman-induced seizures in the brain correspond to concentrations where 
the nAChR-responses are completely blocked, while the NMDA-R are only partially 
inhibited. Nevertheless, since the concentration of drug in different parts of the brain 
may vary (Yokogawa et al. 1992), it may be that the inhibitions both of  NMDA-R 
and of nAChR influence the effects against soman at the late stage. The brain 
concentration of procyclidine 5 minutes after soman exposure is expected to have 
effects on nAChR and on NMDA-R as well. The above calculated brain concentration 
of procyclidine after 5 minutes may therefore be overestimated as the inhibition of 
nAChR and NMDA-R may reduce the amount of mAChR block required to stop 
seizures. The narrower range of IC50 values for procyclidine at the different receptor 
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types may actually make procyclidine more useful as it may help against other 
symptoms of the OP poisoning than only the muscarinic.  
 
For nicotine-induced seizures (Gao et al. 1998) the potencies are similar for all three 
drugs. The brain concentrations for the anticholinergic Parkinson drugs at the ED50, 
calculated as described above, are 6 µM, 2 µM and 7 µM for biperiden, procyclidine 
and trihexphenidyl. These data indicate that both NMDA-R and nAChR may be 
significant in these seizures, which is reasonable as nicotine may stimulate the release 
of glutamate in the CNS (Jensen et al. 2005). Indeed the report by Gao et al. (1999) 
does not identify nAChR as the target of the anti-seizure effects, but leaves open the 
question whether the anti-seizure effects are effects at NMDA-R. 
4.3 Memantine 
As discussed above (section 4.1.1), the data for memantine on the nAChR correspond 
well to the available data from the literature (Buisson and Bertrand 1998; Maskell et 
al. 2003; Aracava et al. 2005). Memantine alone does not stop soman-induced 
seizures, neither after 5 minutes nor after 40 minutes. This may be partially due to its 
lack of anti-muscarinic activity, but may also be due to the rapid dissociation of 
memantine from the NMDA-R (Parsons et al. 1999). The experiments on soman 
induced seizures were done without any centrally acting anti-muscarinic agent, and it 
may be that memantine, similar to gacyclidine (Lallement et al. 1997), may be useful 
if given in addition to atropine and an oxime. 
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4.4 Gacyclidine and MK-801 
MK-801 blocked the nicotine induced Ca2+-response with an IC50 of 1.80 µM. This is 
much lower than the values obtained for isolated receptors in hetorologous expression 
systems (Buisson and Bertrand 1998). This may be due to a different affinity for the 
different subtypes of receptors, and the IC50 of MK-801 to α3β2-receptors is not 
known. Another explanation may be that the measured affinity may differ in different 
systems. This is similar to memantine, where the observed IC50 values varies 20 fold 
between hippocampal neurons and an oocyte expression system (Maskell et al. 2003; 
Aracava et al. 2005). MK-801 showed neither voltage dependence nor use 
dependence. The conclusion from our experiments for nAChR is consistent with 
earlier reports (Briggs and McKenna 1996; Buisson and Bertrand 1998). 
 
Only a small difference in IC50 was seen between racemic gacyclidine and (-)-
gacyclidine at the nAChR. This is similar to what is seen for the NMDA-R, where, 
surprisingly, no difference is seen between the racemate and the pure isomer. This 
was concluded in studies on NMDA-R (Ring and Tansø, unpublished data) and 
recently confirmed independently (Helene Hirbec, private communication) and in 
models of neurotoxicity (Drian et al. 1999). In both cases, however, differences are 
seen between the pure isomers. (-)-gacyclidine showed a use-dependent manner of 
block, while the results for the racemate was not significant. This may be due to a lack 
of sensitivity in the method, or it may be that there is a difference in the manner of 
block between the different isomers. The (+) isomer was not available for testing in 
this study. 
 
4.4.1 nAChR may be the “non-NMDA” binding sites of gacyclidine 
The non-NMDA binding sites in rat brain has been described in two reports 
(Hirbec et al. 2001c, 2001b). The binding was described as uniform in the forebrain 
and a more discrete distribution in the cerebellum. The authors did not succeed in 
identifying the site, and no target was suggested , but interestingly we now observe 
that the distribution reported for this site is in fairly good accordance with the 
distribution of nAChR in the CNS (Gotti and Clementi 2004). This data, together with 
our finding that gacyclidine blocks the nAChR, makes the nAChRs a good candidate 
for these “non-NMDA” binding sites of gacyclidine.  
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4.4.2 Clinical relevance of gacyclidine 
It was claimed that gacyclidine shows less neurotoxixity than classical NMDA-R 
antagonists like MK-801 (Hirbec et al. 2001a). It has been shown to be 
neuroprotective in several different animal and human studies (Lallement et al. 1997; 
Lepeintre et al. 2004; Fehlings and Baptiste 2005). It was suggested that the “non-
NMDA” binding sites may account for the difference in the neurotoxicity between 
gacyclidine and other NMDA-R antagonists (Hirbec et al. 2001c). This hypotheis 
may implicate the relevance of nAChR in the neuroprotective effects of gacyclidine.  
 
4.5 Caramiphen 
Caramiphen blocks the nAChR-response with an IC50 that is two orders of magnitude 
lower than for NMDA-R (Ring and Tansø, unpublished data). Its potency at the 
mAChR (Hudkins et al. 1991), in turn, is two orders of magnitude higher than that at 
the nAChR. These data strongly suggest that caramiphen is effective only through its 
antimuscarinic effects. This is consistent with the observation that caramiphen does 
not stop soman-induced seizures after 40 minutes, but stops seizures 5 minutes after 
soman exposure (Shih et al. 1999). Nevertheless, it appears to be more effective than 
scopolamine, a pure mAChR antagonist (Raveh et al. 2002) and this may be due to its 
additional effects at the nAChR.  
4.6 Novel bis-quarternary pyridine compounds 
There seems to be a clear relationship between the chain length of these drugs, and 
their potency at the neuronal nAChR-receptors, with the longer chain lengths giving 
an increased block. The drugs with a chain-length from 1-3 carbon atoms gave no 
block at 100 µM, which is a maximal concentration considered relevant for these 
drugs. With the drugs with chain lengths from 4 to 10 carbon atoms the IC50 values 
were monotonically decreasing. This was completely unexpected since the 
corresponding relationship between response and chain length for the muscle nAChR 
is bell-shaped, with a maximum block for a 5 carbon chain, and less block for longer 
or shorter chain-lengths (John Tattersall, personal communication). It is interesting to 
note that the classical ganglionic open-channel blocker hexamethonium has a 6 
carbon chain between two positive charges.  
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Our data indicate a use-dependent mechanism for block for SH63 (chain length 10). 
Since use-dependence in the present case is associated with open-channel block, this 
is somewhat surprising. (+)-tubocurarine is a known competitive antagonist for 
neuronal and muscle nAChR (Dwoskin and Crooks 2001), and (+)-tubocurarine has a 
similar structure to SH63 with regard to the classical structure-activity relationship at 
nAChRs. At the muscle nAChR SH63 also seems to block in a competitive manner as 
seen by the results on guinea pig diaphragm (John Tattersall, personal 
communication). It should be noted, however, that the nAChRs are classical models 
for allosteric interactions (Lena and Changeux 1993), and the blocking action of 
SH63 may be a result of mixed competitive and non-competitive blocking actions. 
Another possibility is that the IC50 values of different nAChR subtypes are 
sufficiently different to give rise to an apparent non-competitive block. Further studies 
may resolve this.  
 
The clinical relevance of these observations remains to be clarified. The relevant 
maximal blood plasma concentration is thought to be about 100 µM (Tattersall 1993).  
Since all these compounds have two positive charges they are unlikely to cross the 
blood-brain barrier well enough to give a significant concentration in the brain. 
Therefore, their effect on the CNS is dependent on special pharmaceutical 
formulations or the delivery of these drugs in the form of pro drugs, which might 
reduce their effect on the muscle nAChR. The autonomous ganglia, however, are 
located outside the blood-brain barrier and these compounds may alleviate the 
symptoms of OP poisoning caused by excessive activation of the autonomic nervous 
system, including hypertension and tachycardia. In addition, the novel synthetic 
pyridines were synthesized primarily with intention to target muscle nAChr. It is 
therefore important to take into account the action of the drugs also at the ganglia 
when selecting the most apropriate drug to use. Our data help in discriminating 
between the drugs and suggest that one might choose a lesser potent blocker (i.e. a 
shorter length pyridine) in order to minimize effects on the autonomic nervous 
system. 
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CONCLUSIONS 
The screening method developed was convenient and efficient in screening different 
compounds for their inhibitory action at nAChR. It also proved reliable in 
characterising different types of block as well as the amount (i.e. the IC50) of block. 
The robustness of the method suggests that it may be further refined and applied to 
quantify subtypes of nAChR, although coexpressed in the same cell line. 
 
The anti-cholinergic Parkinson drugs procyclidine, biperiden and trihexphenidyl 
blocked the nAChR-response in a use and voltage dependent manner. Although these 
drugs are closely related in chemical structure, there is little correlation between their 
relative potencies at nAChr, mAChR and NMDA-R. The IC50 are in the order mAChR 
< nAChR < NMDA-R for all three drugs. The abundance of nAChR in the CNS, 
taken together with the relative high potencies at nAChR, suggests a role for the 
effects of the drugs at nAChR in the inhibition of organophosphate-induced seizures. 
 
Gacyclidine also blocks nAChR-responses in a use dependent manner. Both the 
racemate and the (-)-isomers are about 10 times less potent at nAChR than at NMDA-
R, which distinguishes gacyclidine from the anticholinergic Parkinson drugs. The 
finding that gacyclidine blocks the nAChR-response and the observation that the 
distribution of the“non-NMDA” binding sites for gacyclidine correlates with the 
expression of nAChR in the CNS, suggests that these are identical. Further studies 
should be undertaken to clarify this hypothesis. 
 
The novel bis-quarternary pyridine compounds block nAChR. The structure-activity 
relationship indicates that, for the range of chain length in this study, C1 to C10, the 
inhibiting potency increases with chain-length of the linker between the pyridine 
rings. This is in contrast to the data on muscle nAChR, where a 5 carbon linker had 
the highest potency. These data should be taken into consideration when choosing the 
compound to develop as an oxime or inhibit muscle nAChR, since a potent block of 
ganglionic nAChR may not be desirable. On the other hand, if oxime delivery to the 
CNS is desirable, e.g when the blood brain barrier is compromised, then the longest 
chain, C10, would be the candidate of choice.  
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